Выбор оптимальных наборов белков в качестве серологических онкомаркерных сигнатур
Нарыжный С.Н.1 , Легина О.К.1
1. Петербургский институт ядерной физики им. Б.П. Константинова Национального исследовательского центра “Курчатовский институт”, Санкт-Петербург, Россия
На сегодняшний день описано достаточно много онкомаркеров, как потенциальных, так и применяемых в клинике. Хотя некоторые из них успешно используются в диагностике и лечении, ни один из них в полной мере не удовлетворяет потребностям онкологии. Поэтому поиск новых маркеров продолжается. Здесь мультиомные технологии, такие как геномика, транскриптомика и метаболомика, очень важны, но протеомика играет центральную роль, поскольку биомаркеры опухолей в основном представляют собой белки. Особое внимание уделяется белкам плазмы/сыворотки крови, так как кровь является самым популярным источником получения информации о здоровье пациента. Чтобы повысить чувствительность и специфичность анализа, весьма перспективным подходом выглядит оценка уровней не просто отдельных белков, а их определённых наборов. Этому и посвящён данный обзор.
Нарыжный С.Н., Легина О.К. (2025) Выбор оптимальных наборов белков в качестве серологических онкомаркерных сигнатур. Биомедицинская химия, 71(3), 163-194.
Нарыжный С.Н. и др. Выбор оптимальных наборов белков в качестве серологических онкомаркерных сигнатур // Биомедицинская химия. - 2025. - Т. 71. -N 3. - С. 163-194.
Нарыжный С.Н. и др., "Выбор оптимальных наборов белков в качестве серологических онкомаркерных сигнатур." Биомедицинская химия 71.3 (2025): 163-194.
Нарыжный, С. Н., Легина, О. К. (2025). Выбор оптимальных наборов белков в качестве серологических онкомаркерных сигнатур. Биомедицинская химия, 71(3), 163-194.
Список литературы
Bhatt A.N., Mathur R., Farooque A., Verma A., Dwarakanath B.S. (2010) Cancer biomarkers — current perspectives. Indian J. Med. Res., 132(2), 129–149. Scholar google search
Polanski M., Anderson N.L. (2006) Alist of candidate cancer biomarkers for targeted proteomics. Biomarker Insights, 1, 1–48. CrossRef Scholar google search
Paik Y.-K., Kim H., Lee E.-Y., Kwon M.-S., Cho S.Y. (2008) Overview and introduction to clinical proteomics. Methods Mol. Biol., 428, 1–31. CrossRef Scholar google search
Nanjappa V., Thomas J.K., Marimuthu A., Muthusamy B., Radhakrishnan A., Sharma R., Ahmad Khan A., Balakrishnan L., Sahasrabuddhe N.A., Kumar S., Jhaveri B.N., Sheth K.V., Kumar Khatana R., Shaw P.G., Srikanth S.M., Mathur P.P., Shankar S., Nagaraja D., Christopher R,. Mathivanan S., Raju R., Sirdeshmukh R., Chatterjee A., Simpson R.J., Harsha H.C., Pandey A., Prasad T.S. (2014) Plasma Proteome Database as a resource for proteomics research: 2014 update. Nucleic Acids Res., 42(Database issue), D959-D965. CrossRef Scholar google search
Luque-Garcia J.L., Neubert T.A. (2007) Sample preparation for serum/plasma profiling and biomarker identification by mass spectrometry. J. Chromatogr. A, 1153(1–2), 259–276. CrossRef Scholar google search
Paulovich A.G., Whiteaker J.R., Hoofnagle A.N., Wang P. (2008) The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline. Proteomics Clin. Appl., 2(10–11), 1386–1402. CrossRef Scholar google search
Omenn G.S., States D.J., Adamski M., Blackwell T.W., Menon R., Hermjakob H., Apweiler R., Haab B.B., Simpson R.J., Eddes J.S., Kapp E.A., Moritz R.L., Chan D.W., Rai A.J., Admon A., Aebersold R., Eng J., Hancock W.S., Hefta S.A., Meyer H., Paik Y.-K., Yoo J.-S., Ping P., Pounds J., Adkins J., Qian X., Wang R., Wasinger V., Wu C.Y., Zhao X., Zeng R., Archakov A., Tsugita A., Beer I., Pandey A., Pisano M., Andrews P., Tammen H., Speicher D.W., Hanash S.M. (2005) Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics, 5(13), 3226–3245. CrossRef Scholar google search
Surinova S., Schiess R., Hüttenhain R., Cerciello F., Wollscheid B., Aebersold R. (2011) On the development of plasma protein biomarkers. J. Proteome Res., 10(1), 5–16. CrossRef Scholar google search
Parker C.E., Borchers C.H. (2014) Mass spectrometry based biomarker discovery, verification, and validation — quality assurance and control of protein biomarker assays. Mol. Oncol., 8(4), 840–858. CrossRef Scholar google search
Hochstrasser D.F., Sanchez J.-C., Appel R.D. (2002) Proteomics and its trends facing nature’s complexity. Proteomics, 2(2), 807–812. CrossRef Scholar google search
Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., Mills G.B., Simone C., Fishman D.A., Kohn E.C., Liotta L.A. (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet, 359(9306), 572–577. CrossRef Scholar google search
Schiess R., Wollscheid B., Aebersold R. (2009) Targeted proteomic strategy for clinical biomarker discovery. Mol. Oncol., 3(1), 33–44. CrossRef Scholar google search
Geyer P.E., Kulak N.A., Pichler G., Holdt L.M., Teupser D., Mann M. (2016) Plasma proteome profiling to assess human health and disease. Cell Systems, 2(3), 185–195. CrossRef Scholar google search
Geyer P.E., Holdt L.M., Teupser D., Mann M. (2017) Revisiting biomarker discovery by plasma proteomics. Mol. Syst. Biol., 13(9), 942. CrossRef Scholar google search
Farrah T., Deutsch E.W., Omenn G.S., Campbell D.S., Sun Z., Bletz J.A., Mallick P., Katz J.E., Malmström J., Ossola R., Watts J.D., Lin B., Zhang H., Moritz R.L., Aebersold R. (2011) A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. Mol. Cell. Proteomics, 10(9), M110.006353. CrossRef Scholar google search
Cox J., Hein M.Y., Luber C.A., Paron I., Nagaraj N., Mann M. (2014) Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell. Proteomics, 13(9), 2513–2526. CrossRef Scholar google search
Abramowicz A., Wojakowska A., Gdowicz-Klosok A., Polanska J., Rodziewicz P., Polanowski P., Namysl-Kaletka A., Pietrowska M., Wydmanski J., Widlak P. (2015) Identification of serum proteome signatures of locally advanced and metastatic gastric cancer: a pilot study. J. Transl. Med., 13, 304. CrossRef Scholar google search
Anderson N.L., Anderson N.G. (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics, 1(11), 845–867. CrossRef Scholar google search
Hortin G.L., Sviridov D., Anderson N.L. (2008) High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. Clin. Chem., 54(10), 1608–1616. CrossRef Scholar google search
Skates S.J., Gillette M.A., la Baer J., Carr S.A., Anderson L., Liebler D.C., Ransohoff D., Rifai N., Kondratovich M., Težak Ž., Mansfield E., Oberg A.L., Wright I., Barnes G., Gail M., Mesri M., Kinsinger C.R., Rodriguez H., Boja E.S. (2013) Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies. J. Proteome Res., 12(12), 5383–5394. CrossRef Scholar google search
Candia J., Cheung F., Kotliarov Y., Fantoni G., Sellers B., Griesman T., Huang J., Stuccio S., Zingone A., Ryan B.M., Tsang J.S., Biancotto A. (2017) Assessment of variability in the SOMAscan assay. Sci. Rep., 7, 14248. CrossRef Scholar google search
Cui M., Cheng C., Zhang L. (2022) High-throughput proteomics: a methodological mini-review. Lab. Invest., 102(11), 1170–1181. CrossRef Scholar google search
Pang W.W., Abdul-Rahman P.S., Wan-Ibrahim W.I., Hashim O.H. (2010) Can the acute-phase reactant proteins be used as cancer biomarkers? Int. J. Biol. Markers, 25(1), 1–11. CrossRef Scholar google search
Abernethy T.J., Avery O.T. (1941) The occurrence during acute infections of a protein not normally present in the blood: I. Distribution of the reactive protein in patient's sera and the effect of calcium on the flocculation reaction with C polysaccharide of pneumococcus. J. Exp. Med., 73(2), 173–182. CrossRef Scholar google search
Nagaraju G.P., Aliya S., Alese O.B. (2015) Role of adiponectin in obesity related gastrointestinal carcinogenesis. Cytokine Growth Factor Rev., 26(1), 83–93. CrossRef Scholar google search
Boccellino M., Pinto F., Ieluzzi V., Giovane A., Quagliuolo L., Fariello C., Coppola M., Carlucci A., Santini M., Ferati K., Bexheti-Ferati A., Giordano A., di Domenico M. (2019) Proteomics analysis of human serum of patients with non-small-cell lung cancer reveals proteins as diagnostic biomarker candidates. J. Cell. Physiol., 234(12), 23798–23806. CrossRef Scholar google search
Ercetin E., Richtmann S., Delgado B.M., Gomez-Mariano G., Wrenger S., Korenbaum E., Liu B., de Luca D., Kühnel M.P., Jonigk D., Yuskaeva K., Warth A., Muley T., Winter H., Meister M., Welte T., Janciauskiene S., Schneider M.A. (2019) Clinical significance of SERPINA1 gene and its encoded alpha1-antitrypsin protein in NSCLC. Cancers, 11(9), 1306. CrossRef Scholar google search
Fan N., Kang R., Ge X., Li M., Liu Y., Chen H., Gao C. (2014) Identification alpha-2-HS-glycoprotein precursor and tubulin beta chain as serology diagnosis biomarker of colorectal cancer. Diagn. Pathol., 9, 53. CrossRef Scholar google search
Bertuzzi M., Marelli C., Bagnati R., Colombi A., Fanelli R., Saieva C., Ceroti M., Bendinelli B., Caini S., Airoldi L., Palli D. (2015) Plasma clusterin as a candidate pre-diagnosis marker of colorectal cancer risk in the Florence cohort of the European Prospective Investigation into Cancer and Nutrition: a pilot study. BMC Cancer, 15, 56. CrossRef Scholar google search
Pietrowska M., Jelonek K., Michalak M., Roś M., Rodziewicz P., Chmielewska K., Polański K., Polańska J., Gdowicz-Kłosok A., Giglok M., Suwiński R., Tarnawski R., Dziadziuszko R., Rzyman W., Widłak P. (2014) Identification of serum proteome components associated with progression of non-small cell lung cancer. Acta Biochim. Pol., 61(2), 325–331. CrossRef Scholar google search
Zhao P., Wu J., Lu F., Peng X., Liu C., Zhou N., Ying M. (2019) The imbalance in the complement system and its possible physiological mechanisms in patients with lung cancer. BMC Cancer, 19, 201. CrossRef Scholar google search
Yang Y., Zhao S., Fan Y., Zhao F., Liu Q., Hu W., Liu D., Fan K., Wang J., Wang J. (2009) Detection and identification of potential biomarkers of non-small cell lung cancer. Technol. Cancer Res. Treat., 8(6), 455–466. CrossRef Scholar google search
Song D., Yue L., Zhang J., Ma S., Zhao W., Guo F., Fan Y., Yang H., Liu Q., Zhang D., Xia Z., Qin P., Jia J., Yue M., Yu J., Zheng S., Yang F., Wang J. (2016) Diagnostic and prognostic significance of serum apolipoprotein C-I in triple-negative breast cancer based on mass spectrometry. Cancer Biol. Ther., 17(6), 635–647. CrossRef Scholar google search
Lee H.-B., Kang U.-B., Moon H.-G., Lee J., Lee K.-M., Yi M., Park Y.S., Lee J.W., Yu J.-H., Choi S.H., Cho S.H., Lee C., Han W., Noh D.-Y. (2015) Development and validation of a novel plasma protein signature for breast cancer diagnosis by using multiple reaction monitoring-based mass spectrometry. Anticancer Res., 35(11), 6271–6279. Scholar google search
Chong P.-K., Lee H., Loh M.C.S., Choong L.-Y., Lin Q., So J.B.Y., Lim K.H., Soo R.A., Yong W.P., Chan S.P., Smoot D.T., Ashktorab H., Yeoh K.G., Lim Y.P. (2010) Upregulation of plasma C9 protein in gastric cancer patients. Proteomics, 10(18), 3210–3221. CrossRef Scholar google search
Bharali D., Banerjee B.D., Bharadwaj M., Husain S.A., Kar P. (2018) Expression analysis of apolipoproteins AI & AIV in hepatocellular carcinoma: a protein-based hepatocellular carcinoma-associated study. Indian J. Med. Res., 147(4), 361–368. CrossRef Scholar google search
Guo J., Jing R., Zhong J.-H., Dong X., Li Y.-X., Liu Y.-K., Huang T.-R., Zhang C.-Y. (2017) Identification of CD14 as a potential biomarker of hepatocellular carcinoma using iTRAQ quantitative proteomics. Oncotarget, 8(37), 62011–62028. CrossRef Scholar google search
Deutsch E.W., Omenn G.S., Sun Z., Maes M., Pernemalm M., Palaniappan K.K., Letunica N., Vandenbrouck Y., Brun V., Tao S.C., Yu X., Geyer P.E., Ignjatovic V., Moritz R.L., Schwenk J.M. (2021) Advances and utility of the human plasma proteome. J. Proteome Res., 20(12), 5241–5263. CrossRef Scholar google search
Abramson F.P., Jenkins J., Ostchega Y. (1982) Effects of cancer and its treatments on plasma concentration of alpha 1-acid glycoprotein and propranolol binding. Clin. Pharmacol. Ther., 32(5), 659–663. CrossRef Scholar google search
Ciereszko A., Dietrich M.A., Słowińska M., Nynca J., Ciborowski M., Kisluk J., Michalska-Falkowska A., Reszec J., Sierko E., Nikliński J.(2019) Identification of protein changes in the blood plasma of lung cancer patients subjected to chemotherapy using a 2D-DIGE approach. PLOS One, 14(10), e0223840. CrossRef Scholar google search
Verathamjamras C., Chantaraamporn J., Sornprachum T., Mutapat P., Chokchaichamnankit D., Mingkwan K., Luevisadpibul V., Srisomsap C., Chutipongtanate S., Svasti J., Champattanachai V. (2023) Label-free quantitative proteomics reveals aberrant expression levels of LRG, C9, FN, A1AT and AGP1 in the plasma of patients with colorectal cancer. Clin. Proteomics, 20(1), 15. CrossRef Scholar google search
Janciauskiene S., Wrenger S., Günzel S., Gründing A.R., Golpon H., Welte T. (2021) Potential roles of acute phase proteins in cancer: why do cancer cells produce or take up exogenous acute phase protein alpha1-antitrypsin? Front. Oncol., 11, 622076. CrossRef Scholar google search
Fischer K., Kettunen J., Würtz P., Haller T., Havulinna A.S., Kangas A.J., Soininen P., Esko T., Tammesoo M.-L., Mägi R., Smit S., Palotie A., Ripatti S., Salomaa V., Ala-Korpela M., Perola M., Metspalu A. (2014) Biomarker profiling by nuclear magnetic resonance spectroscopy for the prediction of all-cause mortality: an observational study of 17,345 persons. PLOS Med., 11(2), e1001606. CrossRef Scholar google search
Ayyub A., Saleem M., Fatima I., Tariq A., Hashmi N., Musharraf S.G. (2016) Glycosylated alpha-1-acid glycoprotein 1 as a potential lung cancer serum biomarker. Int. J. Biochem. Cell Biol., 70, 68–75. CrossRef Scholar google search
Jabir R.S., Ho G.F., Annuar M.A.B.A., Stanslas J. (2018) Plasma alpha-1-acid glycoprotein as a potential predictive biomarker for non-haematological adverse events of docetaxel in breast cancer patients. Biomarkers, 23(2), 142–146. CrossRef Scholar google search
Balmaña M., Giménez E., Puerta A., Llop E., Figueras J., Fort E., Sanz-Nebot V., de Bolós C., Rizzi A., Barrabés S., de Frutos M., Peracaula R. (2016) Increased α1-3 fucosylation of α-1-acid glycoprotein (AGP) in pancreatic cancer. J. Proteomics, 132, 144–154. CrossRef Scholar google search
Tanabe K., Kitagawa K., Kojima N., Iijima S. (2016) Multifucosylated alpha-1-acid glycoprotein as a novel marker for hepatocellular carcinoma. J. Proteome Res., 15(9), 2935–2944. CrossRef Scholar google search
Chantaraamporn J., Champattanachai V., Khongmanee A., Verathamjamras C., Prasongsook N., Mingkwan K., Luevisadpibul V., Chutipongtanate S., Svasti J. (2020) Glycoproteomic analysis reveals aberrant expression of complement C9 and fibronectin in the plasma of patients with colorectal cancer. Proteomes, 8(3), 26. CrossRef Scholar google search
Gao F., Zhang X., Whang S., Zheng C. (2014) Prognostic impact of plasma ORM2 levels in patients with stage II colorectal cancer. Ann. Clin. Lab. Sci., 44(4), 388–393. Scholar google search
El-Akawi Z.J., Al-Hindawi F.K., Bashir N.A. (2008) Alpha-1 antitrypsin (alpha1-AT) plasma levels in lung, prostate and breast cancer patients. Neuro Endocrinol. Lett., 29(4), 482–484. Scholar google search
Farrokhi Yekta R., Arefi Oskouie A., Rezaei Tavirani M., Mohajeri-Tehrani M.R., Soroush A.R. (2018) Decreased apolipoprotein A4 and increased complement component 3 as potential markers for papillary thyroid carcinoma: a proteomic study. Int. J. Biol. Markers, 33(4), 455–462. CrossRef Scholar google search
Lobo M.D.P., Moreno F.B.M.B., Souza G.H.M.F., Verde S.M.M.L., Moreira R.A., Monteiro-Moreira A.C.D. (2017) Label-free proteome analysis of plasma from patients with breast cancer: stage-specific protein expression. Front. Oncol., 7, 14. CrossRef Scholar google search
Pérez-Holanda S., Blanco I., Menéndez M., Rodrigo L. (2014) Serum concentration of alpha-1 antitrypsin is significantly higher in colorectal cancer patients than in healthy controls. BMC Cancer, 14, 355. CrossRef Scholar google search
Liang Y., Ma T., Thakur A., Yu H., Gao L., Shi P., Li X., Ren H., Jia L., Zhang S., Li Z., Chen M. (2015) Differentially expressed glycosylated patterns of α-1-antitrypsin as serum biomarkers for the diagnosis of lung cancer. Glycobiology, 25(3), 331–340. CrossRef Scholar google search
Jaberie H., Hosseini S.V., Naghibalhossaini F. (2020) Evaluation of alpha 1-antitrypsin for the early diagnosis of colorectal cancer. Pathol. Oncol. Res., 26(2), 1165–1173. CrossRef Scholar google search
Repetto O., de Re V., Mussolin L., Tedeschi M., Elia C., Bianchi M., Buffardi S., Sala A., Burnelli R., Mascarin M. (2020) Proteomic profiles and biological processes of relapsed vs. non-relapsed pediatric Hodgkin lymphoma. Int. J. Mol. Sci., 21(6), 2185. CrossRef Scholar google search
Zhao J., Fan Y.-X., Yang Y., Liu D.-L., Wu K., Wen F.-B., Zhang C.-Y., Zhu D.-Y., Zhao S. (2015) Identification of potential plasma biomarkers for esophageal squamous cell carcinoma by a proteomic method. Int. J. Clin. Exp. Pathol., 8(2), 1535–1544. Scholar google search
Wu C.-C., Lu Y.-T., Yeh T.-S., Chan Y.-H., Dash S., Yu J.-S. (2021) Identification of fucosylated SERPINA1 as a novel plasma marker for pancreatic cancer using lectin affinity capture coupled with iTRAQ-based quantitative glycoproteomics. Int. J. Mol. Sci. 22(11), 6079. CrossRef Scholar google search
Wang W., Wang S., Zhang M. (2020) Evaluation of kininogen 1, osteopontin and α-1-antitrypsin in plasma, bronchoalveolar lavage fluid and urine for lung squamous cell carcinoma diagnosis. Oncol. Lett., 19(4), 2785–2792. CrossRef Scholar google search
Shah A.K., Hartel G., Brown I., Winterford C., Na R., Cao K.-A.L., Spicer B.A., Dunstone M.A., Phillips W.A., Lord R.V., Barbour A.P., Watson D.I., Joshi V., Whiteman D.C., Hill M.M. (2018) Evaluation of serum glycoprotein biomarker candidates for detection of esophageal adenocarcinoma and surveillance of Barrett’s esophagus. Mol. Cell. Proteomics, 17(12), 2324–2334. CrossRef Scholar google search
Sandanayake N.S., Sinclair J., Andreola F., Chapman M.H., Xue A., Webster G.J., Clarkson A., Gill A., Norton I.D., Smith R.C., Timms J.F., Pereira S.P. (2011) A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures. Br. J. Cancer, 105(9), 1370–1378. CrossRef Scholar google search
Brkic S., Salkic A., Nuhbegovic S., Brkic F., Umihanic S. (2011) Influence of surgical therapy on serum values of alpha 1-antitrypsin in patients with head and neck tumors. Medicinski Arhiv, 65(2), 99–101. Scholar google search
Abdul-Rahman P.S., Lim B.-K., Hashim O.H. (2007) Expression of high-abundance proteins in sera of patients with endometrial and cervical cancers: analysis using 2-DE with silver staining and lectin detection methods. Electrophoresis, 28(12), 1989–1996. CrossRef Scholar google search
Liu Y., Luo X., Hu H., Wang R., Sun Y., Zeng R., Chen H. (2012) Integrative proteomics and tissue microarray profiling indicate the association between overexpressed serum proteins and non-small cell lung cancer. PLOS One, 7(12), e51748. CrossRef Scholar google search
Kopylov A.T., Stepanov A.A., Malsagova K.A., Soni D., Kushlinsky N.E., Enikeev D.V., Potoldykova N.V., Lisitsa A.V., Kaysheva A.L. (2020) Revelation of proteomic indicators for colorectal cancer in initial stages of development. Molecules, 25(3), 619. CrossRef Scholar google search
Canales N.A.G., Marina V.M., Castro J.S., Jiménez A.A., Mendoza-Hernández G., McCarron E.L., Roman M.B., Castro-Romero J.I. (2014) A1BG and C3 are overexpressed in patients with cervical intraepithelial neoplasia III. Oncol. Lett., 8(2), 939–947. CrossRef Scholar google search
Kim J.H., Kim Y.-W., Kim I.-W., Park D.C., Kim Y.W., Lee K.-H., Jang C.K., Ahn W.S. (2013) Identification of candidate biomarkers using the Experion™ automated electrophoresis system in serum samples from ovarian cancer patients. Int. J. Oncol., 42(4), 1257–1262. CrossRef Scholar google search
Gaziev U.M., Kit O.I., Frantsiyants E.M., Kozlova L., Mezentsev S.S. (2016) Alpha-2-macroglobulin as the marker for pancreatic cancer process direction. J. Clin. Oncol., 34(15_suppl), e15686–e15686. CrossRef Scholar google search
Opstal-van Winden A.W.J., Krop E.J.M., Kåredal M.H., Gast M.-C.W., Lindh C.H., Jeppsson M.C., Jönsson B.A.G., Grobbee D.E., Peeters P.H.M., Beijnen J.H., van Gils C.H., Vermeulen R.C.H. (2011) Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study. BMC Cancer, 11, 381. CrossRef Scholar google search
Taguchi O., Gabazza E.C., Yoshida M., Yamakami T., Kobayashi H., Shima T. (1996) High plasma level of plasmin-alpha 2-plasmin inhibitor complex is predictor of poor prognosis in patients with lung cancer. Clin. Chim. Acta, 244(1), 69–81. CrossRef Scholar google search
Cavalcante M.S., Torres-Romero J.C., Lobo M.D.P., Moreno F.B.M.B., Bezerra L.P., Lima D.S., Matos J.C., Moreira R.A., Monteiro-Moreira A.C.O. (2016) A panel of glycoproteins as candidate biomarkers for early diagnosis and treatment evaluation of B-cell acute lymphoblastic leukemia. Biomarker Res., 4, 1. CrossRef Scholar google search
Ivancic M.M., Megna B.W., Sverchkov Y., Craven M., Reichelderfer M., Pickhardt P.J., Sussman M.R., Kennedy G.D. (2020) Noninvasive detection of colorectal carcinomas using serum protein biomarkers. J. Surg. Res., 246, 160–169. CrossRef Scholar google search
Guldvik I.J., Zuber V., Braadland P.R., Grytli H.H., Ramberg H., Lilleby W., Thiede B., Zucknick M., Saatcioglu F., Gislefoss R., Kvåle R., George A., Grönberg H., Wiklund F., Neal D.E., Gnanapragasam V.J., Taskén K.A., Mills I.G. (2020) Identification and validation of leucine-rich α-2-glycoprotein 1 as a noninvasive biomarker for improved precision in prostate cancer risk stratification. Eur. Urol. Open Sci., 21, 51–60. CrossRef Scholar google search
Zhang Q., Huang R., Tang Q., Yu Y., Huang Q., Chen Y., Wang G., Wang X. (2018) Leucine-rich alpha-2-glycoprotein-1 is up-regulated in colorectal cancer and is a tumor promoter. OncoTargets Ther., 11, 2745–2752. CrossRef Scholar google search
Holm M., Saraswat M., Joenväärä S., Ristimäki A., Haglund C., Renkonen R. (2018) Colorectal cancer patients with different C-reactive protein levels and 5-year survival times can be differentiated with quantitative serum proteomics. PLOS One, 13(4), e0195354. CrossRef Scholar google search
Gautam P., Nair S.C., Gupta M.K., Sharma R., Polisetty R.V., Uppin M.S., Sundaram C., Puligopu A.K., Ankathi P., Purohit A.K., Chandak G.R., Harsha H.C., Sirdeshmukh R. (2012) Proteins with altered levels in plasma from glioblastoma patients as revealed by iTRAQ-based quantitative proteomic analysis. PLOS One, 7(9), e46153. CrossRef Scholar google search
Andersen J.D., Boylan K.L., Jemmerson R., Geller M.A., Misemer B., Harrington K.M., Weivoda S., Witthuhn B.A., Argenta P., Vogel R.I., Skubitz A.P. (2010) Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients. J. Ovarian Res., 3, 21. CrossRef Scholar google search
Kakisaka T., Kondo T., Okano T., Fujii K., Honda K., Endo M., Tsuchida A., Aoki T., Itoi T., Moriyasu F., Yamada T., Kato H., Nishimura T., Todo S., Hirohashi S. (2007) Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): up-regulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 852(1–2), 257–267. CrossRef Scholar google search
Zhou Y., Zhang X., Zhang J., Fang J., Ge Z., Li X. (2017) LRG1 promotes proliferation and inhibits apoptosis in colorectal cancer cells via RUNX1 activation. PLOS One, 12(4), e0175122. CrossRef Scholar google search
Li D., Zhou L., Ma C., Chen W., Zhang Y., Yu S., Wang D., Zou Y., Wu J., Qiu L. (2019) Comparative analysis of the serum proteome profiles of thyroid cancer: an initial focus on the lipid profile. Oncol. Lett., 18(3), 3349–3357. CrossRef Scholar google search
Stenman U.H., Leinonen J., Alfthan H., Rannikko S., Tuhkanen K., Alfthan O. (1991) A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res., 51(1), 222–226. Scholar google search
Jin Y., Wang W., Wang Q., Zhang Y., Zahid K.R., Raza U., Gong Y. (2022) Alpha-1-antichymotrypsin as a novel biomarker for diagnosis, prognosis, and therapy prediction in human diseases. Cancer Cell Int., 22(1), 156. CrossRef Scholar google search
Jin Y., Wang J., Ye X., Su Y., Yu G., Yang Q., Liu W., Yu W., Cai J., Chen X., Liang Y., Chen Y., Wong B.H.C., Fu X., Sun H. (2016) Identification of GlcNAcylated alpha-1-antichymotrypsin as an early biomarker in human non-small-cell lung cancer by quantitative proteomic analysis with two lectins. Br. J. Cancer, 114(5), 532–544. CrossRef Scholar google search
Miyauchi E., Furuta T., Ohtsuki S., Tachikawa M., Uchida Y., Sabit H., Obuchi W., Baba T., Watanabe M., Terasaki T., Nakada M. (2018) Identification of blood biomarkers in glioblastoma by SWATH mass spectrometry and quantitative targeted absolute proteomics. PLOS One, 13(3), e0193799. CrossRef Scholar google search
Li H., Sun L., Chen L., Kang Z., Hao G., Bai F. (2022) Effects of adiponectin, plasma D-dimer, inflammation and tumor markers on clinical characteristics and prognosis of patients with ovarian cancer. J. Med. Biochem., 41(1), 71–78. CrossRef Scholar google search
Yildirim A., Bilici M., Cayir K., Yanmaz V., Yildirim S., Tekin S.B. (2009) Serum adiponectin levels in patients with esophageal cancer. Jpn. J. Clin. Oncol., 39(2), 92–96. CrossRef Scholar google search
Goktas S., Yilmaz M.I., Caglar K., Sonmez A., Kilic S., Bedir S. (2005) Prostate cancer and adiponectin. Urology, 65(6), 1168–1172. CrossRef Scholar google search
Dieplinger H., Dieplinger B. (2015) Afamin — a pleiotropic glycoprotein involved in various disease states. Clin. Chim. Acta, 446, 105–110. CrossRef Scholar google search
Melmer A., Fineder L., Lamina C., Kollerits B., Dieplinger B., Braicu I., Sehouli J., Cadron I., Vergote I., Mahner S., Zeimet A.G., Castillo-Tong D.C., Ebenbichler C.F., Zeillinger R., Dieplinger H. (2013) Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer — a study by the OVCAD consortium. Gynecol. Oncol., 128(1), 38–43. CrossRef Scholar google search
Dieplinger H., Ankerst D.P., Burges A., Lenhard M., Lingenhel A., Fineder L., Buchner H., Stieber P. (2009) Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Cancer Epidemiol. Biomarkers Prev., 18(4), 1127–1133. CrossRef Scholar google search
Chang T.-T., Ho C.-H. (2020) Plasma proteome atlas for differentiating tumor stage and post-surgical prognosis of hepatocellular carcinoma and cholangiocarcinoma. PLOS One, 15(8), e0238251. CrossRef Scholar google search
Humphries J.M., Penno M.A.S., Weiland F., Klingler-Hoffmann M., Zuber A., Boussioutas A., Ernst M., Hoffmann P. (2014) Identification and validation of novel candidate protein biomarkers for the detection of human gastric cancer. Biochim. Biophys. Acta, 1844(5), 1051–1058. CrossRef Scholar google search
Oñate-Ocaña L.F., Aiello-Crocifoglio V., Gallardo-Rincón D., Herrera-Goepfert R., Brom-Valladares R., Carrillo J.F., Cervera E., Mohar-Betancourt A. (2007) Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann. Surg. Oncol., 14(2), 381–389. CrossRef Scholar google search
Lis C.G., Grutsch J.F., Vashi P.G., Lammersfeld C.A. (2003) Is serum albumin an independent predictor of survival in patients with breast cancer? J. Parenter. Enteral Nutr., 27(1), 10–15. CrossRef Scholar google search
Boonpipattanapong T., Chewatanakornkul S. (2006) Preoperative carcinoembryonic antigen and albumin in predicting survival in patients with colon and rectal carcinomas. J. Clin. Gastroenterol., 40(7), 592–595. CrossRef Scholar google search
Suh B., Park S., Shin D.W., Yun J.M., Keam B., Yang H.-K., Ahn E., Lee H., Park J.H., Cho B. (2014) Low albumin-toglobulin ratio associated with cancer incidence and mortality in generally healthy adults. Ann. Oncol., 25(11), 2260–2266. CrossRef Scholar google search
Fujii T., Tokuda S., Nakazawa Y., Kurozumi S., Obayashi S., Yajima R., Shirabe K. (2020) Implications of low serum albumin as a prognostic factor of long-term outcomes in patients with breast cancer. In Vivo, 34(4), 2033–2036. CrossRef Scholar google search
Cohen A., Wang E., Chisholm K.A., Kostyleva R., O’Connor-McCourt M., Pinto D.M. (2013) A mass spectrometry-based plasma protein panel targeting the tumor microenvironment in patients with breast cancer. J. Proteomics, 81, 135–147. CrossRef Scholar google search
Pugia M.J., Valdes R., Jortani S.A. (2007) Bikunin (urinary trypsin inhibitor): structure, biological relevance, and measurement. Adv. Clin. Chem., 44, 223–245. CrossRef Scholar google search
Greco M., de Mitri M., Chiriacò F., Leo G., Brienza E., Maffia M. (2009) Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: association to tumor derived alpha-N-acetylgalactosaminidase activity. Cancer Lett., 283(2), 222–229. CrossRef Scholar google search
Lu Z., Wang F., Liang M. (2017) SerpinC1/Antithrombin III in kidney-related diseases. Clin. Sci., 131(9), 823–831. CrossRef Scholar google search
Cao X., Cao Z., Ou C., Zhang L., Chen Y., Li Y., Zhu B., Shu H. (2021) Combination of serum paraoxonase/arylesterase 1 and antithrombin-III is a promising non-invasion biomarker for discrimination of AFP-negative HCC versus liver cirrhosis patients. Clin. Res. Hepatol. Gastroenterol., 45(5), 101583. CrossRef Scholar google search
Dowling P., O’Driscoll L., Meleady P., Henry M., Roy S., Ballot J., Moriarty M., Crown J., Clynes M. (2007) 2-D difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins. Electrophoresis, 28(23), 4302–4310. CrossRef Scholar google search
Dabrowska M., Prokopowicz J., Kemona H., Kretowska J., Kulik S., Głuszczak M. (1988) Serum antithrombin III and alpha-2-antiplasmin concentration in patients with lung carcinoma. Folia Haematologica, 115(5), 641–646. Scholar google search
Ren L., Yi J., Li W., Zheng X., Liu J., Wang J., Du G. (2019) Apolipoproteins and cancer. Cancer Med., 8(16), 7032–7043. CrossRef Scholar google search
Georgila K., Vyrla D., Drakos E. (2019) Apolipoprotein A-I (ApoA-I), immunity, inflammation and cancer. Cancers, 11(8), 1097. CrossRef Scholar google search
Cheng T., Dai X., Zhou D.-L., Lv Y., Miao L.-Y. (2015) Correlation of apolipoprotein A-I kinetics with survival and response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer. Med. Oncol., 32(1), 407. CrossRef Scholar google search
Chang H., Wei J.-W., Chen K., Zhang S., Han F., Lu L.-X., Xiao W.-W., Gao Y.-H. (2018) Apolipoprotein A-I is a prognosticator of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy. J. Cancer, 9(4), 702–710. CrossRef Scholar google search
Chang S.-C., Lin W.-L., Chang Y.-F., Lee C.-T., Wu J.-S., Hsu P.-H., Chang C.-F. (2019) Glycoproteomic identification of novel plasma biomarkers for oral cancer. J. Food Drug Anal., 27(2), 483–493. CrossRef Scholar google search
Wang X.-P., Li X.-H., Zhang L., Lin J.-H., Huang H., Kang T., Mao M.-J., Chen H., Zheng X. (2016) High level of serum apolipoprotein A-I is a favorable prognostic factor for overall survival in esophageal squamous cell carcinoma. BMC Cancer, 16, 516. CrossRef Scholar google search
Shi C., Gong S., Wu A., Yang S., Zou D., Zhang Y., Wu N., Ma C., Shi S., Chen Y., Wu Y., Zheng X., Huang Z., Ding J., Ouyang G., Mu Q. (2022) Decreased serum apolipoprotein A1 level predicts poor prognosis of patients with de novo myelodysplastic syndromes. BMC Cancer, 22, 127. CrossRef Scholar google search
Hachem H., Favre G., Ghalim N., Puchois P., Fruchart J.C., Soula G. (1987) Quantitative abnormalities of lipoprotein particles in multiple myeloma. J. Clin. Chem. Clin. Biochem., 25(10), 675–679. CrossRef Scholar google search
Honda K., Okusaka T., Felix K., Nakamori S., Sata N., Nagai H., Ioka T., Tsuchida A., Shimahara T., Shimahara M., Yasunami Y., Kuwabara H., Sakuma T., Otsuka Y., Ota N., Shitashige M., Kosuge T., Büchler M.W., Yamada T. (2012) Altered plasma apolipoprotein modifications in patients with pancreatic cancer: protein characterization and multi-institutional validation. PLOS One, 7(10), e46908. CrossRef Scholar google search
Liu Y., Sogawa K., Sunaga M., Umemura H., Satoh M., Kazami T., Yoshikawa M., Tomonaga T., Yokosuka O., Nomura F. (2014) Increased concentrations of apo A-I and apo A-II fragments in the serum of patients with hepatocellular carcinoma by magnetic beads-assisted MALDI-TOF mass spectrometry. Am. J. Clin. Pathol., 141(1), 52–61. CrossRef Scholar google search
Malik G., Ward M.D., Gupta S.K., Trosset M.W., Grizzle W.E., Adam B.-L., Diaz J.I., Semmes O.J. (2005) Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin. Cancer Res, 11(3), 1073–1085. CrossRef Scholar google search
de Bont J.M., den Boer M.L., Reddingius R.E., Jansen J., Passier M., van Schaik R.H.N., Kros J.M., Sillevis Smitt P.A.E., Luider T.H., Pieters R. (2006) Identification of apolipoprotein A-II in cerebrospinal fluid of pediatric brain tumor patients by protein expression profiling. Clin. Chem., 52(8), 1501–1509. CrossRef Scholar google search
Gómez B.B., López-Cortés R., Casas-Nebra F.J., Vázquez-Estévez S., Pérez-Fentes D., Chantada-Vázquez M.D.P., Bravo S.B., Núñez C. (2021) Detection of circulating serum protein biomarkers of non-muscle invasive bladder cancer after protein corona-silver nanoparticles analysis by SWATH-MS. Nanomaterials, 11(9), 2384. CrossRef Scholar google search
Li B., An H.J., Kirmiz C., Lebrilla C.B., Lam K.S., Miyamoto S. (2008) Glycoproteomic analyses of ovarian cancer cell lines and sera from ovarian cancer patients show distinct glycosylation changes in individual proteins. J. Proteome Res., 7(9), 3776–3788. CrossRef Scholar google search
Wang M., Wang J., Jiang H. (2019) Diagnostic value of apolipoprotein C-I, transthyretin and apolipoprotein C-III in gastric cancer. Oncol. Lett., 17(3), 3227–3232. CrossRef Scholar google search
Yi J., Ren L., Wu J., Li W., Zheng X., Du G., Wang J. (2019) Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for gastric cancer. Ann. Transl. Med., 7(16), 380. CrossRef Scholar google search
Fan Y., Shi L., Liu Q., Dong R., Zhang Q., Yang S., Fan Y., Yang H., Wu P., Yu J., Zheng S., Yang F., Wang J. (2009) Discovery and identification of potential biomarkers of papillary thyroid carcinoma. Mol. Cancer, 8, 79. CrossRef Scholar google search
Fu T., Zhou Y., Mao S. (2023) The expression and clinical significance of apolipoprotein C1 in cervix cancer. Eur. J. Gynaecol. Oncol., 44(6), 67–73. CrossRef Scholar google search
Dufresne J., Bowden P., Thavarajah T., Florentinus-Mefailoski A., Chen Z.Z., Tucholska M., Norzin T., Ho M.T., Phan M., Mohamed N., Ravandi A., Stanton E., Slutsky A.S., dos Santos C.C., Romaschin A., Marshall J.C., Addison C., Malone S., Heyland D., Scheltens P., Killestein J., Teunissen C., Diamandis E.P., Siu K.W.M., Marshall J.G. (2019) The plasma peptides of breast versus ovarian cancer. Clin. Proteomics, 16, 43. CrossRef Scholar google search
Zhou Y., Luo G. (2020) Apolipoproteins, as the carrier proteins for lipids, are involved in the development of breast cancer. Clin. Transl. Oncol., 22(11), 1952–1962. CrossRef Scholar google search
Zhao Z., Zou S., Guan X., Wang M., Jiang Z., Liu Z., Li C., Lin H., Liu X., Yang R., Gao Y., Wang X. (2018) Apolipoprotein E overexpression is associated with tumor progression and poor survival in colorectal cancer. Front. Genet., 9, 650. CrossRef Scholar google search
Kemp S.B., Carpenter E.S., Steele N.G., Donahue K.L., Nwosu Z.C., Pacheco A., Velez-Delgado A., Menjivar R.E., Lima F., The S., Espinoza C.E., Brown K., Long D., Lyssiotis C.A., Rao A., Zhang Y., Pasca di Magliano M., Crawford H.C. (2021) Apolipoprotein E promotes immune suppression in pancreatic cancer through NF-κB-mediated production of CXCL1. Cancer Res., 81(16), 4305–4318. CrossRef Scholar google search
Xue Y., Huang S., Huang J., Li S., Zhang C., Zhou X. (2020) Identification of apolipoprotein E as a potential diagnostic biomarker of nasopharyngeal carcinoma. Cancer Manag. Res., 12, 8943–8950. CrossRef Scholar google search
Xu X., Wan J., Yuan L., Ba J., Feng P., Long W., Huang H., Liu P., Cai Y., Liu M., Luo J., Li L. (2016) Serum levels of apolipoprotein E correlates with disease progression and poor prognosis in breast cancer. Tumour Biol., 37, 15959–15966. CrossRef Scholar google search
Tsai I-J., Su E.C.-Y., Tsai I-L., Lin C.-Y. (2021) Clinical assay for the early detection of colorectal cancer using mass spectrometric wheat germ agglutinin multiple reaction monitoring. Cancers, 13(9), 2190. CrossRef Scholar google search
Wang Y.-B., Zhou B.-X., Ling Y.-B., Xiong Z.-Y., Li R.-X., Zhong Y.-S., Xu M.-X., Lu Y., Liang H., Chen G.-H., Yao Z.-C., Deng M.-H. (2019) Decreased expression of ApoF associates with poor prognosis in human hepatocellular carcinoma. Gastroenterol. Rep., 7(5), 354–360. CrossRef Scholar google search
Jing X., Piao Y.-F., Liu Y., Gao P.-J. (2010) Beta2-GPI: a novel factor in the development of hepatocellular carcinoma. J. Cancer Res. Clin. Oncol., 136(11), 1671–1680. CrossRef Scholar google search
Mandili G., Notarpietro A., Khadjavi A., Allasia M., Battaglia A., Lucatello B., Frea B., Turrini F., Novelli F., Giribaldi G., Destefanis P. (2018) Beta-2-glycoprotein-1 and alpha-1-antitrypsin as urinary markers of renal cancer in von Hippel-Lindau patients. Biomarkers, 23(2), 123–130. CrossRef Scholar google search
Lee S.-W., Kim I.J., Jeong B.Y., Choi M.-H., Kim J.Y., Kwon K.-H., Lee J.W., Yu A., Shin M.-G. (2012) Use of MDLC-DIGE and LC-MS/MS to identify serum biomarkers for complete remission in patients with acute myeloid leukemia. Electrophoresis, 33(12), 1863–1872. CrossRef Scholar google search
Cao W.-Q., Jiang B.-Y., Huang J.-M., Zhang L., Liu M.-Q., Yao J., Wu M.-X., Zhang L.-J., Kong S.-Y., Wang Y., Yang P.-Y. (2019) Straightforward and highly efficient strategy for hepatocellular carcinoma glycoprotein biomarker discovery using a nonglycopeptide-based mass spectrometry pipeline. Anal. Chem., 91(19), 12435–12443. CrossRef Scholar google search
Jiang J., Wu C., Luo G., Zheng L., Chen L., Zhang X., Xu N. (2011) Expression of apolipoprotein M in human hepatocellular carcinoma tissues. Acta Histochem., 113(1), 53–57. CrossRef Scholar google search
Li L., Dong M., Wang X.-G. (2016) The implication and significance of beta 2 microglobulin: a conservative multifunctional regulator. Chin. Med. J., 129(4), 448–455. CrossRef Scholar google search
Sequeira J., Sengupta S., Mhatre B. (2021) Serum beta-2 microglobulin analysis in patients with oral squamous cell carcinoma. Natl. J. Maxillofac. Surg., 12(2), 227–232. CrossRef Scholar google search
Li G., Feng G., Gentil-Perret A., Genin C., Tostain J. (2008) Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. J. Urol., 180(2), 510–514. CrossRef Scholar google search
Kou W., Li B., Shi Y., Zhao Y., Yu Q., Zhuang J., Xu Y., Peng W. (2022) High complement protein C1q levels in pulmonary fibrosis and non-small cell lung cancer associated with poor prognosis. BMC Cancer, 22, 110. CrossRef Scholar google search
Xu B., Lv W., Li X., Zhang L., Lin J. (2019) Prognostic genes of hepatocellular carcinoma based on gene coexpression network analysis. J. Cell. Biochem., 120(7), 11616–11623. CrossRef Scholar google search
Chinello C., Cazzaniga M., de Sio G., Smith A.J., Grasso A., Rocco B., Signorini S., Grasso M., Bosari S., Zoppis I., Mauri G., Magni F. (2015) Tumor size, stage and grade alterations of urinary peptidome in RCC. J. Transl. Med., 13(1), 332. CrossRef Scholar google search
Nedjadi T., Benabdelkamal H., Albarakati N., Masood A., Al-Sayyad A., Alfadda A.A., Alanazi I.O., Al-Ammari A., Al-Maghrabi J. (2020) Circulating proteomic signature for detection of biomarkers in bladder cancer patients. Sci. Rep., 10, 10999. CrossRef Scholar google search
Daugan M.V., Revel M., Russick J., Dragon-Durey M.-A., Gaboriaud C., Robe-Rybkine T., Poillerat V., Grunenwald A., Lacroix G., Bougouin A., Meylan M., Verkarre V., Oudard S.M., Mejean A., Vano Y.A., Perkins G., Validire P., Cathelineau X., Sanchez-Salas R., Damotte D., Fremeaux-Bacchi V., Cremer I., Sautès-Fridman C., Fridman W.H., Roumenina L.T. (2021) Complement C1s and C4d as prognostic biomarkers in renal cancer: emergence of noncanonical functions of C1s. Cancer Immunol. Res., 9(8), 891–908. CrossRef Scholar google search
Gürz S., Çelik B., Menteşe A., Us Altay D. (2018) Diagnostic value of signal peptide-complement C1r/C1s, Uegf, and Bmp1-epidermal growth factor domain-containing protein 1 on serum and tissue samples in non-small cell lung cancer. Turk Gogus Kalp Damar Cerrahisi Dergisi, 26(2), 246–253. CrossRef Scholar google search
Tan G., Liu Q., Tang X., Kang T., Li Y., Lu J., Zhao X., Tang F. (2016) Diagnostic values of serum cathepsin B and D in patients with nasopharyngeal carcinoma. BMC Cancer, 16, 241. CrossRef Scholar google search
Wei S., Liu W., Xu M., Qin H., Liu C., Zhang R., Zhou S., Li E., Liu Z., Wang Q. (2022) Cathepsin F and fibulin-1 as novel diagnostic biomarkers for brain metastasis of non-small cell lung cancer. Br. J. Cancer, 126(12), 1795–1805. CrossRef Scholar google search
Dou X., Lu J., Yu Y., Yi Y., Zhou L. (2024) Determination of tumor marker screening for lung cancer using ROC curves. Dis. Markers, 2024, 4782618. CrossRef Scholar google search
Chen Z., Liu X., Shang X., Qi K., Zhang S. (2021) The diagnostic value of the combination of carcinoembryonic antigen, squamous cell carcinoma-related antigen, CYFRA 21-1, neuron-specific enolase, tissue polypeptide antigen, and progastrin-releasing peptide in small cell lung cancer discrimination. Int. J. Biol. Markers, 36(4), 36–44. CrossRef Scholar google search
Zhang J., Yang X., Wei L., Tan H., Chen J., Li W., Chan K., Su Y., Zhao L., Hu S., Zhong S., Xiao Y., Liu H. (2020) Improved diagnostic value by combining plasma PON1 level with tumor biomarkers in colorectal cancer patients. J. Cancer, 11(22), 6491–6496. CrossRef Scholar google search
Chen C., Chen Q., Dong Y., Liu X. (2020) The clinical significance of sICAM-1 in differentiating benign breast lesions from breast cancer. Ann. Clin. Lab. Sci., 50(5), 650–656. Scholar google search
Huang Z.-B., Zhou X., Xu J., Du Y.-P., Zhu W., Wang J., Shu Y.-Q., Liu P. (2014) Prognostic value of preoperative serum tumor markers in gastric cancer.World J. Clin. Oncol., 5(2), 170–176. CrossRef Scholar google search
Liu W., Liu B., Xin L., Zhang Y., Chen X., Zhu Z., Lin Y. (2007) Down-regulated expression of complement factor I: a potential suppressive protein for gastric cancer identified by serum proteome analysis. Clin. Chim. Acta, 377(1–2), 119–126. CrossRef Scholar google search
Riihilä P., Nissinen L., Farshchian M., Kallajoki M., Kivisaari A., Meri S., Grénman R., Peltonen S., Peltonen J., Pihlajaniemi T., Heljasvaara R., Kähäri V.-M. (2017) Complement component C3 and complement factor B promote growth of cutaneous squamous cell carcinoma. Am. J. Pathol., 187(5), 1186–1197. CrossRef Scholar google search
Wu P., Shi J., Sun W., Zhang H. (2021) The prognostic value of plasma complement factor B (CFB) in thyroid carcinoma. Bioengineered, 12(2), 12854–12866. CrossRef Scholar google search
Chambers A.G., Percy A.J., Yang J., Camenzind A.G., Borchers C.H. (2013) Multiplexed quantitation of endogenous proteins in dried blood spots by multiple reaction monitoring-mass spectrometry. Mol. Cell. Proteomics, 12(3), 781–791. CrossRef Scholar google search
Bouwens T.A.M., Trouw L.A., Veerhuis R., Dirven C.M.F., Lamfers M.L.M., Al-Khawaja H. (2015) Complement activation in glioblastoma multiforme pathophysiology: evidence from serum levels and presence of complement activation products in tumor tissue. J. Neuroimmunol., 278, 271–276. CrossRef Scholar google search
Rajkumar T., Amritha S., Sridevi V., Gopal G., Sabitha K., Shirley S., Swaminathan R. (2022) Identification and validation of plasma biomarkers for diagnosis of breast cancer in South Asian women. Sci. Rep., 12, 100. CrossRef Scholar google search
Yang Y., Wan C., Li H., Zhu H., La Y., Xi Z., Chen Y., Jiang L., Feng G., He L. (2006) Altered levels of acute phase proteins in the plasma of patients with schizophrenia. Anal. Chem., 78(11), 3571–3576. CrossRef Scholar google search
Cui T., Chen Y., Knösel T., Yang L., Zöller K., Galler K., Berndt A., Mihlan M., Zipfel P.F., Petersen I. (2011) Human complement factor H is a novel diagnostic marker for lung adenocarcinoma. Int. J. Oncol., 39(1), 161–168. CrossRef Scholar google search
Cheng Z.-Z., Corey M.J., Pärepalo M., Majno S., Hellwage J., Zipfel P.F., Kinders R.J., Raitanen M., Meri S., Jokiranta T.S. (2005) Complement factor H as a marker for detection of bladder cancer. Clin. Chem., 51(5), 856–863. CrossRef Scholar google search
Suzuki R., Okubo Y., Takagi T., Sugimoto M., Sato Y., Irie H., Nakamura J., Takasumi M., Kato T., Hashimoto M., Kobashi R., Hikichi T., Ohira H. (2022) The complement C3a-C3a receptor axis regulates epithelial-to-mesenchymal transition by activating the ERK pathway in pancreatic ductal adenocarcinoma. Anticancer Res., 42(3), 1207–1215. CrossRef Scholar google search
Huang Y., Chen F., Zhang L., Lv Q., Yan J., Cui W. (2021) MALDI-TOF-MS analysis in the discovery and identification of the serum peptide pattern of pancreatic ductal adenocarcinoma. Lab. Med., 52(6), 558–566. CrossRef Scholar google search
Li C.-J., Xia H.-L., Wu Y.-M., Ding G., Xu D.-D. (2019) Significance of detecting serum complement C3 and C4 in patients with multiple myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 27(2), 472–476. CrossRef Scholar google search
Jiang F., Liu H., Liu Z., Song J., Li L., Ding K., Ren Y., Peng F., Shao Z., Fu R. (2017) High serum levels of complements C3 and C4 as novel markers for myeloma bone disease. Ann. Hematol., 96(2), 331–333. CrossRef Scholar google search
Dowling P., Clarke C., Hennessy K., Torralbo-Lopez B., Ballot J., Crown J., Kiernan I., O’Byrne K.J., Kennedy M.J., Lynch V., Clynes M. (2012) Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. Int. J. Cancer, 131(4), 911–923. CrossRef Scholar google search
Ajona D., Pajares M.J., Corrales L., Perez-Gracia J.L., Agorreta J., Lozano M.D., Torre W., Massion P.P., de-Torres J.P., Jantus-Lewintre E., Camps C., Zulueta J.J., Montuenga L.M., Pio R. (2013) Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer. J. Natl. Cancer Inst., 105(18), 1385–1393. CrossRef Scholar google search
Corrales L., Ajona D., Rafail S., Lasarte J.J., Riezu-Boj J.I., Lambris J.D., Rouzaut A., Pajares M.J., Montuenga L.M., Pio R. (2012) Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J. Immunol., 189(9), 4674–4683. CrossRef Scholar google search
Hameed B.H., Abdulsatar Al-Rayahi I., Muhsin S.S. (2022) The preoperative serum levels of the anaphylatoxins C3a and C5a and their association with clinico-pathological factors in breast cancer patients. Arch. Razi Inst., 77(5), 1873–1879. CrossRef Scholar google search
Wang S., Hu W., Xie Y., Wu H., Jia Z., Zhang Z., Zhang X. (2022) Functional genetic variants in complement component 7 confer susceptibility to gastric cancer. PeerJ, 10, e12816. CrossRef Scholar google search
Fishelson Z., Kirschfink M. (2019) Complement C5b-9 and cancer: mechanisms of cell damage, cancer counteractions, and approaches for intervention. Front. Immunol., 10, 752. CrossRef Scholar google search
Joshi V., Shah A., Brown I., Winterford C., Hill M. (2017) Complement component C9 as a new biomarker for esophageal adenocarcinoma. J. Clin. Oncol., 35(4_suppl), 19. CrossRef Scholar google search
Takakura M., Yokomizo A., Tanaka Y., Kobayashi M., Jung G., Banno M., Sakuma T., Imada K., Oda Y., Kamita M., Honda K., Yamada T., Naito S., Ono M. (2012) Carbonic anhydrase I as a new plasma biomarker for prostate cancer. ISRN Oncol., 2012, 768190. CrossRef Scholar google search
Wang D.-B., Lu X.-K., Zhang X., Li Z.-G., Li C.-X. (2016) Carbonic anhydrase 1 is a promising biomarker for early detection of non-small cell lung cancer. Tumour Biol., 37, 553–559. CrossRef Scholar google search
Wang W., Chang J., Jia B., Liu J. (2020) The blood biomarkers of thyroid cancer. Cancer Manag. Res., 12, 5431–5438. CrossRef Scholar google search
Cui R., Wang C., Zhao Q., Wang Y., Li Y. (2020) Serum carboxypeptidase N1 serves as a potential biomarker complementing CA15-3 for breast cancer. Anticancer Agents Med. Chem., 20(17), 2053–2065. CrossRef Scholar google search
Chang S.T., Zahn J.M., Horecka J., Kunz P.L., Ford J.M., Fisher G.A., Le Q.T., Chang D.T., Ji H., Koong A.C. (2009) Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. J. Transl. Med., 7, 105. CrossRef Scholar google search
Pforte A., Schiessler A., Gais P., Beer B., Ehlers M., Schütt C., Ziegler-Heitbrock H.W. (1994) Expression of CD14 correlates with lung function impairment in pulmonary sarcoidosis. Chest, 105(2), 349–354. CrossRef Scholar google search
Seyedmajidi S., Seyedmajidi M., Foroughi R., Zahedpasha A., Zolfaghari Saravi Z., Pourbagher R., Bijani A., Motallebnejad M., Monfared Shabestani A., Mostafazadeh A. (2018) Comparison of salivary and serum soluble CD44 levels between patients with oral SCC and healthy controls. Asian Pacific J. Cancer Prev., 19(11), 3059–3063. CrossRef Scholar google search
Nakagawara A., Ikeda K., Tsuneyoshi M., Daimaru Y., Enjoji M., Watanabe I., Iwafuchi M., Sawada T. (1985) Hepatoblastoma producing both alpha-fetoprotein and human chorionic gonadotropin. Clinicopathologic analysis of four cases and a review of the literature. Cancer, 56(7), 1636–1642. CrossRef Scholar google search
Senra Varela A., Lopez Saez J.J., Quintela Senra D. (1997) Serum ceruloplasmin as a diagnostic marker of cancer. Cancer Lett., 121(2), 139–145. CrossRef Scholar google search
Yin H., Lin Z., Nie S., Wu J., Tan Z., Zhu J., Dai J., Feng Z., Marrero J., Lubman D.M. (2014) Mass-selected site-specific core-fucosylation of ceruloplasmin in alcohol-related hepatocellular carcinoma. J. Proteome Res., 13(6), 2887–2896. CrossRef Scholar google search
Mampilly M.O., Ravindran N., Parambil M.S., Nilesh K., Jayagopalan P., Dhamali D. (2021) Assessment of serum selenium and ceruloplasmin in potentially malignant disorders and oral cancer. J. Pharm. Bioall. Sci., 13(Suppl 2), S989–S992. CrossRef Scholar google search
Sogabe M., Nozaki H., Tanaka N., Kubota T., Kaji H., Kuno A., Togayachi A., Gotoh M., Nakanishi H., Nakanishi T., Mikami M., Suzuki N., Kiguchi K., Ikehara Y., Narimatsu H. (2014) Novel glycobiomarker for ovarian cancer that detects clear cell carcinoma. J. Proteome Res., 13(3), 1624–1635. CrossRef Scholar google search
Harazono A., Kawasaki N., Itoh S., Hashii N., Ishii-Watabe A., Kawanishi T., Hayakawa T. (2006) Site-specific N-glycosylation analysis of human plasma ceruloplasmin using liquid chromatography with electrospray ionization tandem mass spectrometry. Anal. Biochem., 348(2), 259–268. CrossRef Scholar google search
Balmaña M., Sarrats A., Llop E., Barrabés S., Saldova R., Ferri M.J., Figueras J., Fort E., de Llorens R., Rudd P.M., Peracaula R. (2015) Identification of potential pancreatic cancer serum markers: increased sialyl-Lewis X on ceruloplasmin. Clin. Chim. Acta, 442, 56–62. CrossRef Scholar google search
Gao H., Wan Y., Fan X., Dong Y., Ji X., Song W. (2021) The role of cholinesterase in differential diagnosis between gastric cancer and benign gastric diseases. Clin. Lab., 67(2), DOI: 10.7754/Clin.Lab.2020.200525. CrossRef Scholar google search
Shaqi M.A., Rijub-Agha A.K.Y., Hussain R.J. (2023) Serum pseudocholinesterase as a biomarker in the differentiation between gastric cancer and benign gastric diseases. Al-Kindy College Medical Journal, 19(2), 190–195. CrossRef Scholar google search
Lin C.-C., Tsai P., Sun H.-Y., Hsu M.-C., Lee J.-C., Wu I-C., Tsao C.-W., Chang T.-T., Young K.-C. (2014) Apolipoprotein J, a glucose-upregulated molecular chaperone, stabilizes core and NS5A to promote infectious hepatitis C virus virion production. J. Hepatol., 61(5), 984–993. CrossRef Scholar google search
Koltai T. (2014) Clusterin: a key player in cancer chemoresistance and its inhibition. OncoTargets Ther., 7, 447–456. CrossRef Scholar google search
Rasmy H.S., Mohammed H.A., Mohammed E.S., Ahmed A.S.M., Isaac A. (2022) Serum clusterin as a promising diagnostic and prognostic marker for hepatocellular carcinoma after locoregional treatment. Egypt. J. Immunol., 29(2), 26–40. CrossRef Scholar google search
Sansanwal P., Li L., Sarwal M.M. (2015) Inhibition of intracellular clusterin attenuates cell death in nephropathic cystinosis. J. Am. Soc. Nephrol., 26(3), 612–625. CrossRef Scholar google search
Serie D., Myers A.A., Haehn D.A., Parker A.S., Bajalia E., Gonzalez G., Li Q., Wong M.Y., Moser K., Zhou B., Thiel D.D. (2022) Novel plasma glycoprotein biomarkers predict progression-free survival in surgically resected clear cell renal cell carcinoma. Urol. Oncol., 40(4), 168.e11–168.e19. CrossRef Scholar google search
Chen Q.-F., Chang L., Su Q., Zhao Y., Kong B. (2021) Clinical importance of serum secreted clusterin in predicting invasive breast cancer and treatment responses. Bioengineered, 12(1), 278–285. CrossRef Scholar google search
Bellia F., Vecchio G., Rizzarelli E. (2014) Carnosinases, their substrates and diseases. Molecules, 19(2), 2299–2329. CrossRef Scholar google search
Arner P., Henjes F., Schwenk J.M., Darmanis S., Dahlman I., Iresjö B.-M., Naredi P., Agustsson T., Lundholm K., Nilsson P., Rydén M. (2015) Circulating carnosine dipeptidase 1 associates with weight loss and poor prognosis in gastrointestinal cancer. PLOS One, 10(4), e0123566. CrossRef Scholar google search
Schwenk J.M., Igel U., Neiman M., Langen H., Becker C., Bjartell A., Ponten F., Wiklund F., Grцnberg H., Nilsson P., Uhlen M. (2010) Toward next generation plasma profiling via heat-induced epitope retrieval and array-based assays. Mol. Cell. Proteomics, 9(11), 2497–2507. CrossRef Scholar google search
Hart P.C., Rajab I.M., Alebraheem M., Potempa L.A. (2020) C-reactive protein and cancer-diagnostic and therapeutic insights. Front. Immunol., 11, 595835. CrossRef Scholar google search
Bruserud Ø., Aarstad H.H., Tvedt T.H.A. (2020) Combined C-reactive protein and novel inflammatory parameters as a predictor in cancer-what can we learn from the hematological experience? Cancers, 12(7), 1966. CrossRef Scholar google search
Ma L.-N., Liu X.-Y., Lu Z.-H., Wu L.-G., Tang Y.-Y., Luo X., Hu Y.-C., Yan T.-T., Wang Q., Ding X.-C., Xie Y. (2017) Assessment of high-sensitivity C-reactive protein tests for the diagnosis of hepatocellular carcinoma in patients with hepatitis B-associated liver cirrhosis. Oncol. Lett., 13(5), 3457–3464. CrossRef Scholar google search
Fischer K., Theil G., Hoda R., Fornara P. (2012) Serum amyloid A: a biomarker for renal cancer. Anticancer Res., 32(5), 1801–1804. Scholar google search
Lee K.-M., Nam K., Oh S., Lim J., Kim R.K., Shim D., Choi J.-H., Lee S.-J., Yu J.-H., Lee J.W., Ahn S.H., Shin I. (2015) ECM1 regulates tumor metastasis and CSC-like property through stabilization of β-catenin. Oncogene, 34(50), 6055–6065. CrossRef Scholar google search
Wang X., Peng Y., Xie M., Gao Z., Yin L., Pu Y., Liu R. (2017) Identification of extracellular matrix protein 1 as a potential plasma biomarker of ESCC by proteomic analysis using iTRAQ and 2D-LC-MS/MS. Proteomics Clin. Appl., 11(9–10), 1600163. CrossRef Scholar google search
Cheng Y., Liu C., Zhang N., Wang S., Zhang Z. (2014) Proteomics analysis for finding serum markers of ovarian cancer. Biomed Res. Int., 2014, 179040. CrossRef Scholar google search
Isgrò M.A., Bottoni P., Scatena R. (2015) Neuron-specific enolase as a biomarker: biochemical and clinical aspects. Adv. Exp. Med. Biol., 867, 125–143. CrossRef Scholar google search
Takashi M., Haimoto H., Tanaka J., Murase T., Kato K. (1989) Evaluation of gamma-enolase as a tumor marker for renal cell carcinoma. J. Urol., 141(4), 830–834. CrossRef Scholar google search
Gong J., Jie Y., Xiao C., Zhou W., Li X., Chen Y., Wu Y., Cao J., Zhang Q., Gao Z., Hu B., Chong Y. (2020) Increased expression of fibulin-1 is associated with hepatocellular carcinoma progression by regulating the notch signaling pathway. Front. Cell Dev. Biol., 8, 478. CrossRef Scholar google search
Watany M.M., Elmashad N.M., Badawi R., Hawash N. (2018) Serum FBLN1 and STK31 as biomarkers of colorectal cancer and their ability to noninvasively differentiate colorectal cancer from benign polyps. Clin. Chim. Acta, 483, 151–155. CrossRef Scholar google search
Xia H., Feng L., Lin L., Jiang Z., Chen J., Shi W., Ying S., Yu M., Ju L., Zhu L., Shi L., Zhang X., Lou J. (2021) Exploration of identifying novel serum biomarkers for malignant mesothelioma using iTRAQ combined with 2D-LC-MS/MS. Environ. Res., 193, 110467. CrossRef Scholar google search
Zhu J., Chen R., Mo L., Tang H., Kuang Y., Fei W., He C., Hu X. (2015) Expression of fibulin-1 predicted good prognosis in patients with colorectal cancer. Am. J Transl. Res., 7(2), 339–347. Scholar google search
Khan R., Gupta N., Kumar R., Sharma M., Kumar L., Sharma A. (2014) Augmented expression of urokinase plasminogen activator and extracellular matrix proteins associates with multiple myeloma progression. Clin. Exp. Metastasis, 31(5), 585–593. CrossRef Scholar google search
Świerzko A.S., Michalski M., Sokołowska A., Nowicki M., Szala-Poździej A., Eppa Ł., Mitrus I., Szmigielska-Kapłon A., Sobczyk-Kruszelnicka M., Michalak K., Gołos A., Wierzbowska A., Giebel S., Jamroziak K., Kowalski M.L., Brzezińska O., Thiel S., Matsushita M., Jensenius J.C., Gajek G., Cedzyński M. (2019) Associations of ficolins with hematological malignancies in patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantations. Front. Immunol., 10, 3097. CrossRef Scholar google search
Sokołowska A., Świerzko A.S., Gajek G., Gołos A., Michalski M., Nowicki M., Szala-Poździej A., Wolska-Washer A., Brzezińska O., Wierzbowska A., Jamroziak K., Kowalski M.L., Thiel S., Matsushita M., Jensenius J.C., Cedzyński M. (2020) Associations of ficolins and mannose-binding lectin with acute myeloid leukaemia in adults. Sci. Rep., 10, 10561. CrossRef Scholar google search
Li Q., Lin Y. (2019) Evaluation of ficolin-3 as a potential prognostic serum biomarker in Chinese patients with esophageal cancer. Genet. Test. Mol. Biomarkers, 23(8), 565–572. CrossRef Scholar google search
Okano T., Kondo T., Kakisaka T., Fujii K., Yamada M., Kato H., Nishimura T., Gemma A., Kudoh S., Hirohashi S. (2006) Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. Proteomics, 6(13), 3938–3948. CrossRef Scholar google search
Andersen J.D., Boylan K.L.M., Xue F.S., Anderson L.B., Witthuhn B.A., Markowski T.W., Higgins L., Skubitz A.P.N. (2010) Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis. Electrophoresis, 31(4), 599–610. CrossRef Scholar google search
Wu A.H., Sell S. (1990) Markers for hepatocellular carcinoma. Immunol. Series, 53, 403–422. Scholar google search
Behne T., Copur M.S. (2012) Biomarkers for hepatocellular carcinoma. Int. J. Hepatol., 2012, 859076. CrossRef Scholar google search
Li D., Mallory T., Satomura S. (2001) AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin. Chim. Acta, 313(1–2), 15–19. CrossRef Scholar google search
Ochieng J., Nangami G., Sakwe A., Moye C., Alvarez J., Whalen D., Thomas P., Lammers P. (2018) Impact of fetuin-A (AHSG) on tumor progression and type 2 diabetes. Int. J. Mol. Sci., 19(8), 2211. CrossRef Scholar google search
Holm M., Joenväärä S., Saraswat M., Mustonen H., Tohmola T., Ristimäki A., Renkonen R., Haglund C. (2019) Identification of several plasma proteins whose levels in colorectal cancer patients differ depending on outcome. FASEB BioAdvances, 1(12), 723–730. CrossRef Scholar google search
Zhang X., Long Q. (2017) Elevated serum plasma fibrinogen is associated with advanced tumor stage and poor survival in hepatocellular carcinoma patients. Medicine (Baltimore), 96(17), e6694. CrossRef Scholar google search
Bailey M.J., Shield-Artin K.L., Oliva K., Ayhan M., Reisman S., Rice G.E. (2013) Stage-specific analysis of plasma protein profiles in ovarian cancer: difference in-gel electrophoresis analysis of pooled clinical samples. J. Carcinog., 12, 10. CrossRef Scholar google search
Yang W., Shi J., Zhou Y., Liu T., Li J., Hong F., Zhang K., Liu N. (2019) Co-expression network analysis identified key proteins in association with hepatic metastatic colorectal cancer. Proteomics Clin. Appl., 13(6), e1900017. CrossRef Scholar google search
Zhu W.L., Fan B.L., Liu D.L., Zhu W.X. (2009) Abnormal expression of fibrinogen gamma (FGG) and plasma level of fibrinogen in patients with hepatocellular carcinoma. Anticancer Res., 29(7), 2531–2534. Scholar google search
Peng H.H., Wang J.N., Xiao L.F., Yan M., Chen S.P., Wang L., Yang K. (2021) Elevated serum FGG levels prognosticate and promote the disease progression in prostate cancer. Front. Genet., 12, 651647. CrossRef Scholar google search
Wang Z., Wang C., Huang X., Shen Y., Shen J., Ying K. (2012) Differential proteome profiling of pleural effusions from lung cancer and benign inflammatory disease patients. Biochim. Biophys. Acta, 1824(4), 692–700. CrossRef Scholar google search
Gerner C., Steinkellner W., Holzmann K., Gsur A., Grimm R., Ensinger C., Obrist P., Sauermann G. (2001) Elevated plasma levels of crosslinked fibrinogen gamma-chain dimer indicate cancer-related fibrin deposition and fibrinolysis. Thromb. Haemost., 85(3), 494–501. CrossRef Scholar google search
Tas F., Bilgin E., Karabulut S., Tastekin D., Duranyildiz D. (2016) Levels of serum fibronectin as a biomarker in gastric cancer patients: correlation with clinical diagnosis and outcome. Mol. Clin. Oncol., 4(4), 655–659. CrossRef Scholar google search
Moon P.-G., Lee J.-E., Cho Y.-E., Lee S.J., Chae Y.S., Jung J.H., Kim I.-S., Park H.Y., Baek M.-C. (2016) Fibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer. Oncotarget, 7(26), 40189–40199. CrossRef Scholar google search
Chai Y.D., Zhang L., Yang Y., Su T., Charugundla P., Ai J., Messadi D., Wong D.T., Hu S. (2016) Discovery of potential serum protein biomarkers for lymph node metastasis in oral cancer. Head Neck, 38(1), 118–125. CrossRef Scholar google search
Kochi N., Tani E., Morimura T., Itagaki T. (1983) Immunohistochemical study of fibronectin in human glioma and meningioma. Acta Neuropathol., 59(2), 119–126. CrossRef Scholar google search
Lin T.-C., Yang C.-H., Cheng L.-H., Chang W.-T., Lin Y.-R., Cheng H.-C. (2019) Fibronectin in cancer: friend or foe. Cells, 9(1), 27. CrossRef Scholar google search
Paizi M., Manaster J., Quitt M., Spira G. (1991) High plasma fibronectin levels in multiple myeloma patients: possible mechanisms and clinical implications. Scand. J. Immunol., 34(3), 285–289. CrossRef Scholar google search
Ivanova T.I., Klabukov I.D., Krikunova L.I., Poluektova M.V., Sychenkova N.I., Khorokhorina V.A., Vorobyev N.V., Gaas M.Y., Baranovskii D.S., Goryainova O.S., Sachko A.M., Shegay P.V., Kaprin A.D., Tillib S.V. (2022) Prognostic value of serum transferrin analysis in patients with ovarian cancer and cancer-related functional iron deficiency: a retrospective case-control study. J. Clin. Med., 11(24), 7377. CrossRef Scholar google search
Chen Z., Liang Z., Chen K., Zhang S., Huang X., Wu G., Zhu X. (2024) Serum ferritin predicted prognosis in patients with nasopharyngeal carcinoma. Sci. Rep., 14, 4311. CrossRef Scholar google search
Essen A., Ozen H., Ayhan A., Ergen A., Tasar C., Remzi F. (1991) Serum ferritin: a tumor marker for renal cell carcinoma. J. Urol., 145(6), 1134–1137. CrossRef Scholar google search
Chiu C.-T., Wang P.-W., Asare-Werehene M., Tsang B.K., Shieh D.-B. (2020) Circulating plasma gelsolin: a predictor of favorable clinical outcomes in head and neck cancer and sensitive biomarker for early disease diagnosis combined with soluble Fas ligand. Cancers, 12(6), 1569. CrossRef Scholar google search
Tsai M.-H., Wu C.-C., Peng P.-H., Liang Y., Hsiao Y.-C., Chien K.-Y., Chen J.-T., Lin S.-J., Tang R.-P., Hsieh L.-L., Yu J.-S. (2012) Identification of secretory gelsolin as a plasma biomarker associated with distant organ metastasis of colorectal cancer. J. Mol. Med. (Berlin), 90(2), 187–200. CrossRef Scholar google search
Lee P.-S., Sampath K., Karumanchi S.A., Tamez H., Bhan I., Isakova T., Gutierrez O.M., Wolf M., Chang Y., Stossel T.P., Thadhani R. (2009) Plasma gelsolin and circulating actin correlate with hemodialysis mortality. J. Am. Soc. Nephrol., 20(5), 1140–1148. CrossRef Scholar google search
Agnani D., Camacho-Vanegas O., Camacho C., Lele S., Odunsi K., Cohen S., Dottino P., Martignetti J.A. (2011) Decreased levels of serum glutathione peroxidase 3 are associated with papillary serous ovarian cancer and disease progression. J. Ovarian Res., 4(1), 18. CrossRef Scholar google search
Psathakis D., Wedemeyer N., Oevermann E., Krug F., Siegers C.P., Bruch H.P. (1998) Blood selenium and glutathione peroxidase status in patients with colorectal cancer. Dis. Colon Rectum, 41(3), 328–335. CrossRef Scholar google search
van Belle S.J.-P. (2004) What is the value of hemoglobin as a prognostic and predictive factor in cancer? Eur. J. Cancer Suppl., 2(2), 11–19. CrossRef Scholar google search
Comunale M.A., Lowman M., Long R.E., Krakover J., Philip R., Seeholzer S., Evans A.A., Hann H.-W.L., Block T.M., Mehta A.S. (2006) Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J. Proteome Res., 5(2), 308–315. CrossRef Scholar google search
Cine N., Baykal Tarik A., Sunnetci D., Canturk Z., Serhatli M., Savli H. (2014) Identification of ApoA1, HPX and POTEE genes by omic analysis in breast cancer. Oncol. Rep., 32(3), 1078–1086. CrossRef Scholar google search
Liao W.-Y., Ho C.-C., Hou H.-H., Hsu T.-H., Tsai M.-F., Chen K.-Y., Chen H.-Y., Lee Y.-C., Yu C.-J., Lee C.-H., Yang P.-C. (2015) Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer. J. Pathol., 235(1), 50–64. CrossRef Scholar google search
Namini N.M., Abdollahi A., Movahedi M., Razavi A.E., Saghiri R. (2021) Association of SERPIND1 expression with grade, stage and presence of metastasis in breast cancer. Indian J. Biochem. Biophys., 58(1), 71–82. CrossRef Scholar google search
Beecken W.-D., Bentas W., Engels K., Glienke W., Urbschat A., Jonas D., Binder J., Scharrer I. (2002) Reduced plasma levels of coagulation factors in relation to prostate cancer. Prostate, 53(2), 160–167. CrossRef Scholar google search
Нарыжный С.Н., Легина О.К. (2021) Гаптоглобин как биомаркер. Биомедицинская химия, 67(2), 105–118. CrossRef Scholar google search
Zhao C., Annamalai L., Guo C., Kothandaraman N., Koh S.C.L., Zhang H., Biswas A., Choolani M. (2007) Circulating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancer. Neoplasia, 9(1), 1–7. CrossRef Scholar google search
Garibay-Cerdenares O.L., Hernández-Ramírez V.I., Osorio-Trujillo J.C., Hernández-Ortíz M., Gallardo-Rincón D., Cantú de León D., Encarnación-Guevara S., Villegas-Pineda J.C., Talamás-Rohana P. (2014) Proteomic identification of fucosylated haptoglobin alpha isoforms in ascitic fluids and its localization in ovarian carcinoma tissues from Mexican patients. J. Ovarian Res., 7, 27. CrossRef Scholar google search
Ye B., Cramer D.W., Skates S.J., Gygi S.P., Pratomo V., Fu L., Horick N.K., Licklider L.J., Schorge J.O., Berkowitz R.S. Mok S.C. (2003) Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin. Cancer Res., 9(8), 2904–2911. Scholar google search
Zhu J., Lin Z., Wu J., Yin H., Dai J., Feng Z., Marrero J., Lubman D.M. (2014) Analysis of serum haptoglobin fucosylation in hepatocellular carcinoma and liver cirrhosis of different etiologies. J. Proteome Res., 13(6), 2986–2997. CrossRef Scholar google search
Wu J., Zhu J., Yin H., Buckanovich R.J., Lubman D.M. (2014) Analysis of glycan variation on glycoproteins from serum by the reverse lectin-based ELISA assay. J. Proteome Res., 13(4), 2197–2204. CrossRef Scholar google search
Naryzhny S., Ronzhina N., Zorina E., Kabachenko F., Zavialova M., Zgoda V., Klopov N., Legina O., Pantina R. (2021) Evaluation of haptoglobin and its proteoforms as glioblastoma markers. Int. J. Mol. Sci., 22(12), 1–12. CrossRef Scholar google search
Epelbaum R., Shalitin C., Segal R., Valansi C., Arselan I., Faraggi D., Leviov M., Ben-Shahar M., Haim N. (1998) Haptoglobin-related protein as a serum marker in malignant lymphoma. Pathol. Oncol. Res., 4(4), 271–276. CrossRef Scholar google search
Rong Y., Jin D., Hou C., Hu J., Wu W., Ni X., Wang D., Lou W. (2010) Proteomics analysis of serum protein profiling in pancreatic cancer patients by DIGE: up-regulation of mannose-binding lectin 2 and myosin light chain kinase 2. BMC Gastroenterol., 10, 68. CrossRef Scholar google search
Ahmed M.B., Almogbel E., Khirry I., Hassan S., Salem T., Saeed A. (2017) Diagnostic and prognostic significance of histidine-rich glycoprotein in acute lymphoblastic leukemia. Open J. Blood Dis., 7, 16–28. CrossRef Scholar google search
Winiarska A., Zareba L., Krolczyk G., Czyzewicz G., Zabczyk M., Undas A. (2019) Decreased levels of histidine-rich glycoprotein in advanced lung cancer: association with prothrombotic alterations. Dis. Markers, 2019, 8170759. CrossRef Scholar google search
Göransson J., Jonsson S., Lasson A. (1996) Pre-operative plasma levels of C-reactive protein, albumin and various plasma protease inhibitors for the pre-operative assessment of operability and recurrence in cancer surgery. Eur. J. Surg. Oncol., 22(6), 607–617. CrossRef Scholar google search
Lee C.-S., Taib N.A.M., Ashrafzadeh A., Fadzli F., Harun F., Rahmat K., Hoong S.M., Abdul-Rahman P.S., Hashim O.H. (2016) Unmasking heavily O-glycosylated serum proteins using perchloric acid: identification of serum proteoglycan 4 and protease C1 inhibitor as molecular indicators for screening of breast cancer. PLOS One, 11(2), e0149551. CrossRef Scholar google search
Yakut M., Özkan H., Karakaya M.F., Erdal H. (2018) Diagnostic and prognostic role of serum interleukin-6 in malignant transformation of liver cirrhosis. Euroasian J. Hepatogastroenterol., 8(1), 23–30. CrossRef Scholar google search
Tanouti I.-A., Fellah H., Haddaji A., Zerrad C., Tahiri M., Badre W., Nfaoui K., Pineau P., Benjelloun S., Ezzikouri S. (2024) High plasma interleukin-6 level, but not IL-6 gene variants, as a predictive marker for the development of hepatocellular carcinoma in a Moroccan population. Int. J. Immunogenet., 51(4), 206–216. CrossRef Scholar google search
Łukaszewicz-Zając M., Mroczko B., Kozłowski M., Nikliński J., Laudański J., Szmitkowski M. (2012) Higher importance of interleukin 6 than classic tumor markers (carcinoembryonic antigen and squamous cell cancer antigen) in the diagnosis of esophageal cancer patients. Dis. Esophagus, 25(3), 242–249. CrossRef Scholar google search
Hamm A., Veeck J., Bektas N., Wild P.J., Hartmann A., Heindrichs U., Kristiansen G., Werbowetski-Ogilvie T., del Maestro R., Knuechel R., Dahl E. (2008) Frequent expression loss of inter-alpha-trypsin inhibitor heavy chain (ITIH) genes in multiple human solid tumors: a systematic expression analysis. BMC Cancer, 8, 25. CrossRef Scholar google search
Jiang X., Bai X.-Y., Li B., Li Y., Xia K., Wang M., Li S., Wu H. (2019) Plasma inter-alpha-trypsin inhibitor heavy chains H3 and H4 serve as novel diagnostic biomarkers in human colorectal cancer. Dis. Markers, 2019, 5069614. CrossRef Scholar google search
Chang Q.-H., Mao T., Tao Y., Dong T., Tang X.-X., Ge G.-H., Xu Z.-J. (2021) Pan-cancer analysis identifies ITIH1 as a novel prognostic indicator for hepatocellular carcinoma. Aging (Albany NY), 13(8), 11096–11119. CrossRef Scholar google search
Chong P.K., Lee H., ZhouJ., Liu S.-C., Loh M.C.S., Wang T.T., Chan S.P., Smoot D.T., Ashktorab H., So J.B.Y., Lim K.H., Yeoh K.G., Lim Y.P. (2010) ITIH3 is a potential biomarker for early detection of gastric cancer. J. Proteome Res., 9(7), 3671–3679. CrossRef Scholar google search
Sun Y., Jin J., Jing H., Lu Y., Zhu Q., Shu C., Zhang Q., Jing D. (2021) ITIH4 is a novel serum biomarker for early gastric cancer diagnosis. Clin. Chim. Acta, 523, 365–373. CrossRef Scholar google search
Ura B., Biffi S., Monasta L., Arrigoni G., Battisti I., di Lorenzo G., Romano F., Aloisio M., Celsi F., Addobbati R., Valle F., Rampazzo E., Brucale M., Ridolfi A., Licastro D., Ricci G. (2021) Two dimensional-difference in gel electrophoresis (2D-DIGE) proteomic approach for the identification of biomarkers in endometrial cancer serum. Cancers, 13(14), 3639. CrossRef Scholar google search
Chapman M.H., Sandanayake N.S., Andreola F., Dhar D.K., Webster G.J., Dooley J.S., Pereira S.P. (2011) Circulating CYFRA 21-1 is a specific diagnostic and prognostic biomarker in biliary tract cancer. J. Clin. Exp. Hepatol., 1(1), 6–12. CrossRef Scholar google search
Brockmann J.G., St Nottberg H., Glodny B., Heinecke A., Senninger N.J. (2000) CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin. Cancer Res., 6(11), 4249–4252. Scholar google search
Pavićević R., Milicić J., Bubanović G., Supe S. (1998) Serum tumor marker CYFRA 21-1 in the diagnostics of NSCLC lung cancer. Collegium Antropologicum, 22(2), 629–635. Scholar google search
Jeong S., Park Y., Cho Y., Kim Y.R., Kim H.-S. (2012) Diagnostic values of urine CYFRA21-1, NMP22, UBC, and FDP for the detection of bladder cancer. Clin. Chim. Acta, 414, 93–100. CrossRef Scholar google search
Cheng Z., Lv Y., Pang S., Bai R., Wang M., Lin S., Xu T., Spalding D., Habib N., Xu R. (2015) Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis. Acta Pharm. Sin. B, 5(3), 194–200. CrossRef Scholar google search
Ma C., Luo C., Yin H., Zhang Y., Xiong W., Zhang T., Gao T., Wang X., Che D., Fang Z., Li L., Xie J., Huang M., Zhu L., Jiang P., Qi W., Zhou T., Yang Z., Wang W., Ma J., Gao G., Yang X. (2018) Kallistatin inhibits lymphangiogenesis and lymphatic metastasis of gastric cancer by downregulating VEGF-C expression and secretion. Gastric Cancer, 21(4), 617–631. CrossRef Scholar google search
Luo L.-Y., Katsaros D., Scorilas A., Fracchioli S., Bellino R., van Gramberen M., de Bruijn H., Henrik A., Stenman U.-H., Massobrio M., van der Zee A.G.J., Vergote I., Diamandis E.P. (2003) The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res., 63(4), 807–811. Scholar google search
David M.K., Leslie S.W. (2024) Prostate-Specific Antigen. In: [StatPearls Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557495/. Scholar google search
Wang J., Wang X., Lin S., Chen C., Wang C., Ma Q., Jiang B. (2013) Identification of kininogen-1 as a serum biomarker for the early detection of advanced colorectal adenoma and colorectal cancer. PLOS One, 8(7), e70519. CrossRef Scholar google search
Yu J., Huang Y., Lin C., Li X., Fang X., Zhong C., Yuan Y., Zheng S. (2018) Identification of kininogen 1 as a serum protein marker of colorectal adenoma in patients with a family history of colorectal cancer. J. Cancer, 9(3), 540–547. CrossRef Scholar google search
Амоев З.В., Алясова А.В., Горшкова Т.Н., Самсонова Е.И., Строкина Е.В., Конторщикова К.Н. (2020) Белки Tumor M2-пируваткиназа, матричная карбоангидраза IX и металлопротеиназа 9 — новые прогностические маркеры почечно-клеточного рака. Современные технологии в медицине, 12(2), 43–49. CrossRef Scholar google search
Lüftner D., Mesterharm J., Akrivakis C., Geppert R., Petrides P.E., Wernecke K.D., Possinger K. (2000) Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res., 20(6D), 5077–5082. Scholar google search
Giatagana E.-M., Berdiaki A., Tsatsakis A., Tzanakakis G.N., Nikitovic D. (2021) Lumican in carcinogenesis — revisited. Biomolecules, 11(9), 1319. CrossRef Scholar google search
Pan S., Chen R., Brand R.E., Hawley S., Tamura Y., Gafken P.R., Milless B.P., Goodlett D.R., Rush J., Brentnall T.A. (2012) Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study. J. Proteome Res., 11(3), 1937–1948. CrossRef Scholar google search
Appunni S., Anand V., Khandelwal M., Seth A., Mathur S., Sharma A. (2017) Altered expression of small leucine-rich proteoglycans (Decorin, Biglycan and Lumican): plausible diagnostic marker in urothelial carcinoma of bladder. Tumour Biol., 39(5), 1010428317699112. CrossRef Scholar google search
Su C., Lin Y., Cai L., Mao Q., Niu J. (2016) Association between mannose-binding lectin variants, haplotypes and risk of hepatocellular carcinoma: a case-control study. Sci. Rep., 6, 32147. CrossRef Scholar google search
Nikkola J., Vihinen P., Vuoristo M.-S., Kellokumpu-Lehtinen P., Kähäri V.-M., Pyrhönen S. (2005) High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin. Cancer Res., 11(14), 5158–5166. CrossRef Scholar google search
Dyachenko E.I., Bel’skaya L.V. (2024) Salivary transmembrane mucins of the MUC1 family (CA 15-3, CA 27.29, MCA) in breast cancer: the effect of human epidermal growth factor receptor 2 (HER2). Cancers, 16(20), 3461. CrossRef Scholar google search
Lawicki S., Bкdkowska G.E., Gacuta-Szumarska E., Szmitkowski M. (2013) The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors. J. Ovarian Res., 6(1), 45. CrossRef Scholar google search
Duk J.M., Aalders J.G., Fleuren G.J., de Bruijn H.W. (1986) CA 125: a useful marker in endometrial carcinoma. Am. J. Obstet. Gynecol., 155(5), 1097–1102. CrossRef Scholar google search
Shimada Y., Watanabe G., Kawamura J., Soma T., Okabe M., Ito T., Inoue H., Kondo M., Mori Y., Tanaka E., Imamura M. (2005) Clinical significance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor markers. Oncology, 68(2–3), 285–292. CrossRef Scholar google search
Maier T., Laubender R.P., Sturm R.A., Klingenstein A., Korting H.C., Ruzicka T., Berking C. (2012) Osteopontin expression in plasma of melanoma patients and in melanocytic tumours. J. Eur. Acad. Dermatol. Venereol., 26(9), 1084–1091. CrossRef Scholar google search
Cho H., Hong S.W., Oh Y.J., Kim M.A., Kang E.S., Lee J.M., Kim S.W., Kim S.H., Kim J.H., Kim Y.T., Lee K. (2008) Clinical significance of osteopontin expression in cervical cancer. J. Cancer Res. Clin. Oncol., 134(8), 909–917. CrossRef Scholar google search
Nedjadi T., Albarakati N., Benabdelkamel H., Masood A., Alfadda A.A., Al-Maghrabi J. (2021) Proteomic profiling of plasma-derived biomarkers in patients with bladder cancer: a step towards clinical translation. Life (Basel), 11(12), 1294. CrossRef Scholar google search
Jackson D., Craven R.A., Hutson R.C., Graze I., Lueth P., Tonge R.P., Hartley J.L., Nickson J.A., Rayner S.J., Johnston C., Dieplinger B., Hubalek M., Wilkinson N., Perren T.J., Kehoe S., Hall G.D., Daxenbichler G., Dieplinger H., Selby P.J,. Banks R.E. (2007) Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin. Cancer Res., 13(24), 7370–7379. CrossRef Scholar google search
Ide H., Yamagishi S.-I., Lu Y., Sakamaki K., Nakajima A., Horiuchi A., Kitamura K., Hisasue S.-I., Muto S., Yamaguchi R., Horie S. (2015) Circulating pigment epithelium-derived factor (PEDF) is associated with pathological grade of prostate cancer. Anticancer Res., 35(3), 1703–1708. Scholar google search
Yang Z., Feng J., Xiao L., Chen X., Yao Y., Li Y., Tang Y., Zhang S., Lu M., Qian Y., Wu H., Shi M. (2020) Tumor-derived peptidoglycan recognition protein 2 predicts survival and antitumor immune responses in hepatocellular carcinoma. Hepatology, 71(5), 1626–1642. CrossRef Scholar google search
Yang L., Cui R., Li Y., Liang K., Ni M., Gu Y. (2020) Hypoxia-induced TGFBI as a serum biomarker for laboratory diagnosis and prognosis in patients with pancreatic ductal adenocarcinoma. Lab. Med., 51(4), 352–361. CrossRef Scholar google search
Kang D.W., Choi K.-Y., Min D.S. (2014) Functional regulation of phospholipase D expression in cancer and inflammation. J. Biol. Chem., 289(33), 22575–22582. CrossRef Scholar google search
Tang J.-H., He W.-J., Huang H., Tan C.-C., Duan Q., Wang K.-J., Yuan X.-Y., Zhu X.-J. (2009) Important roles of glycosylphosphatidylinositol (GPI)-specific phospholipase D and some GPI-anchored proteins in the pathogenesis of hepatocellular carcinoma. Clin. Biochem., 42(4–5), 400–407. CrossRef Scholar google search
Kwaan H.C., McMahon B. (2009) The role of plasminogen-plasmin system in cancer. Cancer Treat. Res., 148, 43–66. CrossRef Scholar google search
Bharadwaj A.G., Holloway R.W., Miller V.A., Waisman D.M. (2021) Plasmin and plasminogen system in the tumor microenvironment: implications for cancer diagnosis, prognosis, and therapy. Cancers, 13(8), 1838. CrossRef Scholar google search
Vecka M., Jáchymová M., Vávrová L., Kodydková J., Macášek J., Urbánek M., Krechler T., Slabý A., Dušková J., Muravská A., Zák A. (2012) Paraoxonase-1 (PON1) status in pancreatic cancer: relation to clinical parameters. Folia Biologica, 58(6), 231–237. CrossRef Scholar google search
Aldonza M.B.D., Son Y.S., Sung H.-J., Ahn J.M., Choi Y.-J., Kim Y.-I., Cho S., Cho J.-Y. (2017) Paraoxonase-1 (PON1) induces metastatic potential and apoptosis escape via its antioxidative function in lung cancer cells. Oncotarget, 8(26), 42817–42835. CrossRef Scholar google search
Ahn S.B., Sharma S., Mohamedali A., Mahboob S., Redmond W.J., Pascovici D., Wu J.X., Zaw T., Adhikari S., Vaibhav V., Nice E.C., Baker M.S. (2019) Potential early clinical stage colorectal cancer diagnosis using a proteomics blood test panel. Clin. Proteomics, 16, 34. CrossRef Scholar google search
Afsar C.U., Gunaldı M., Okuturlar Y., Gedikbası A., Tiken E.E., Kahraman S., Karaca F., Ercolak V., Karabulut M. (2015) Paraoxonase-1 and arylesterase activities in patients with colorectal cancer. Int. J. Clin. Exp. Med., 8(11), 21599–21604. Scholar google search
Akçay M.N., Yilmaz I., Polat M.F., Akçay G. (2003) Serum paraoxonase levels in gastric cancer. Hepato-gastroenterology, 50 Suppl 2, cclxxiii–cclxxv. Scholar google search
Hung M.J., Oremek G.M. (2011) Value of TRAcP 5b as a diagnostic marker for detection of bone metastases in patients with breast cancer. Eur. J. Gynaecol. Oncol., 32(6), 615–618. Scholar google search
Schlesinger M., Broman I., Lugassy G. (1996) The complement system is defective in chronic lymphatic leukemia patients and in their healthy relatives. Leukemia, 10(9), 1509–1513. Scholar google search
Uehara S., Fukuzawa Y., Matuyama T., Gotoh K. (2017) Role of Tyro 3, Axl, and Mer receptors and their ligands (Gas 6, and Protein S) in patients with hepatocellular carcinoma. J. Cancer Ther., 8(2), 112–130. CrossRef Scholar google search
Bushue N., Wan Y.-J.Y. (2010) Retinoid pathway and cancer therapeutics. Adv. Drug Deliv. Rev., 62(13), 1285–1298. CrossRef Scholar google search
Hu X., Huang W., Wang F., Dai Y., Hu X., Yue D., Wang S. (2020) Serum levels of retinol-binding protein 4 and the risk of non-small cell lung cancer: a case-control study. Medicine (Baltimore), 99(31), e21254. CrossRef Scholar google search
Jiao C., Cui L., Ma A., Li N., Si H. (2016) Elevated serum levels of retinol-binding protein 4 are associated with breast cancer risk: a case-control study. PLOS One, 11(12), e0167498. CrossRef Scholar google search
Biaoxue R., Hua L., Wenlong G., Shuanying Y. (2016) Increased serum amyloid A as potential diagnostic marker for lung cancer: a meta-analysis based on nine studies. BMC Cancer, 16, 836. CrossRef Scholar google search
Malle E., Sodin-Semrl S., Kovacevic A. (2009) Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell. Mol. Life Sci., 66(1), 9–26. CrossRef Scholar google search
Wang J.-Y., Zheng Y.-Z., Yang J., Lin Y.-H., Dai S.-Q., Zhang G., Liu W.-L. (2012) Elevated levels of serum amyloid A indicate poor prognosis in patients with esophageal squamous cell carcinoma. BMC Cancer, 12, 365. CrossRef Scholar google search
Kaneti J., Winikoff Y., Zimlichman S., Shainkin-Kestenbaum R. (1984) Importance of serum amyloid A (SAA) level in monitoring disease activity and response to therapy in patients with prostate cancer. Urol. Res., 12(5), 239–241. CrossRef Scholar google search
Zhang G., Sun X., Lv H., Yang X., Kang X. (2012) Serum amyloid A: a new potential serum marker correlated with the stage of breast cancer. Oncol. Lett., 3(4), 940–944. CrossRef Scholar google search
Yokoi K., Raber M.N., Shih L.-C.N., Li D., Hamilton S.R., Fidler I.J., Abbruzzese J.L. (2004) Serum amyloid A (SAA) in patients with pancreatic carcinoma. J. Clin. Oncol., 22(14_suppl), 9649. CrossRef Scholar google search
Lin H.-Y., Tan G.-Q., Liu Y., Lin S.-Q. (2019) The prognostic value of serum amyloid A in solid tumors: a meta-analysis. Cancer Cell Int., 19(1), 62. CrossRef Scholar google search
Levo Y., Wollner S., Treves A.J. (1986) Serum amyloid Pcomponent levels in patients with malignancy. Scand. J. Immunol., 24(2), 147–151. CrossRef Scholar google search
de Nunzio C., Lombardo R., Albisinni S., Gacci M., Tubaro A. (2013) Serum levels of sex hormone binding globulin (SHBG) are not predictive of prostate cancer diagnosis and aggressiveness: results from an Italian biopsy cohort. Int. Braz. J. Urol, 39(6), 793–799. CrossRef Scholar google search
Cheng C.-W., Chang C.-C., Patria Y.N., Chang R.-T., Liu Y.-R., Li F.-A., Shih H.-M., Lin C.-Y. (2018) Sex hormone-binding globulin (SHBG) is a potential early diagnostic biomarker for gastric cancer. Cancer Med., 7(1), 64–74. CrossRef Scholar google search
Gebhardt C., Németh J., Angel P., Hess J. (2006) S100A8 and S100A9 in inflammation and cancer. Biochem. Pharmacol., 72(11), 1622–1631. CrossRef Scholar google search
Petsa A., Pergialiotis V., Konstantopoulos P., Katsichti A., Petrou K., Giannopoulos A., Botsis D., Perrea D. (2017) Serum calprotectin and prealbumin levels among ovarian cancer patients aged 30-45 years. Open J. Obstet. Gynecol., 7, 303–311. CrossRef Scholar google search
Ni Bhriain H., Trovik J., Wik E., Stefansson I.M., Akslen L.A., Salvesen H.B., Staff A.C. (2009) Plasma calprotectin concentrations in women with endometrial carcinoma. Gynecol. Oncol., 114(3), 491–495. CrossRef Scholar google search
Kim H.J., Kang H.J., Lee H., Lee S.T., Yu M.H., Kim H., Lee C. (2009) Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J. Proteome Res., 8(3), 1368–1379. CrossRef Scholar google search
Wang L., Chang E.W.Y., Wong S.C., Ong S.-M., Chong D.Q.Y., Ling K.L. (2013) Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. J. Immunol., 190(2), 794–804. CrossRef Scholar google search
Markowitz J., Carson W.E. 3rd (2013) Review of S100A9 biology and its role in cancer. Biochim. Biophys. Acta, 1835(1), 100–109. CrossRef Scholar google search
Jury C.S., Mcallister E.J., Mackie R.M. (2000) Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br. J. Dermatol., 143(2), 269–274. CrossRef Scholar google search
Polivka J., Gouda M.A., Sharif M., Pesta M., Huang H., Treskova I., Woznica V., Windrichova J., Houfkova K., Kucera R., Fikrle T., Ricar J., Pivovarcikova K., Topolcan O., Janku F. (2024) Predictive significance of combined plasmatic detection of BRAF mutations and S100B tumor marker in early-stage malignant melanoma. Cancer Med., 13(19), e70313. CrossRef Scholar google search
Sehitogulları A., Aslan M., Sayır F., Kahraman A., Demir H. (2014) Serum paraoxonase-1 enzyme activities and oxidative stress levels in patients with esophageal squamous cell carcinoma. Redox Rep., 19(5), 199–205. CrossRef Scholar google search
Zhu H. (2022) Squamous cell carcinoma antigen: clinical application and research status. Diagnostics, 12(5), 1065. CrossRef Scholar google search
Kagohashi K., Satoh H., Kurishima K., Kadono K., Ishikawa H., Ohtsuka M., Sekizawa K. (2008) Squamous cell carcinoma antigen in lung cancer and nonmalignant respiratory diseases. Lung, 186(5), 323–326. CrossRef Scholar google search
Begum F.D., Høgdall C.K., Kjaer S.K., Christensen L., Blaakaer J., Bock J.E., Glud E., Høyer-Hansen G., Ring-Larsen H., Høgdall E.V.S. (2004) The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients. Anticancer Res., 24(3b), 1981–1985. Scholar google search
Arellano-Garcia M.E., Li R., Liu X., Xie Y., Yan X., Loo J.A., Hu S. (2010) Identification of tetranectin as a potential biomarker for metastatic oral cancer. Int. J. Mol. Sci., 11(9), 3106–3121. CrossRef Scholar google search
Lemos-González Y., Rodríguez-Berrocal F.J., Cordero O.J., Gómez C., Páez de la Cadena M. (2007) Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma. Br. J. Cancer, 96(10), 1569–1578. CrossRef Scholar google search
Agrusa J.E., Scull B.P., Abhyankar H.A., Lin H., Ozuah N.W., Chakraborty R., Eckstein O.S., Gulati N., Fattah E.A., El-Mallawany N.K., Rouce R.H., Dreyer Z.E., Brackett J., Margolin J.F., Lubega J., Horton T.M., Bollard C.M., Gramatges M.M., Kamdar K.Y., McClain K.L., Man T.K., Allen C.E. (2020) Defining the inflammatory plasma proteome in pediatric Hodgkin lymphoma. Cancers, 12(12), 3603. CrossRef Scholar google search
Terui S., Moriya Y., Yamamoto H., Koyama Y. (1987) Thyroxine-binding globulin as a marker of liver tumors. Cancer Detect. Prev., 10(5–6), 371–378. Scholar google search
Sieg A., Schönpflug A., Seitz H.K., Kommerell B. (1991) Thyroxine-binding globulin — not a tumor marker of hepatocellular cancer. Zeitschrift fur Gastroenterologie, 29(3), 101–104. Scholar google search
Cui S.-X., Yu X.-F., Qu X.-J. (2016) Roles and signaling pathways of des-γ-carboxyprothrombin in the progression of hepatocellular carcinoma. Cancer Invest., 34(9), 459–464. CrossRef Scholar google search
Yang Y., Li G., Lu Z., Liu Y., Kong J., Liu J. (2021) Progression of prothrombin induced by vitamin K absence-II in hepatocellular carcinoma. Front. Oncol., 11, 726213. CrossRef Scholar google search
Feng X., Song P., Bie P., Jiang P., Ma K., Li X., Wang S., Wang Z., Tang W., Zheng S. (2016) Des-γ-carboxyprothrombin plasma level in diagnosis of hepatocellular carcinoma in a Chinese population undergoing surgery. Med. Sci. Monit., 22, 1663–1672. CrossRef Scholar google search
Jain S., Gautam V., Naseem S. (2011) Acute-phase proteins: as diagnostic tool. J. Pharm. Bioallied Sci., 3(1), 118–127. CrossRef Scholar google search
Lee C.-C., Ding X., Zhao T., Wu L., Perkins S., Du H., Yan C. (2019) Transthyretin stimulates tumor growth through regulation of tumor, immune, and endothelial cells. J. Immunol., 202(3), 991–1002. CrossRef Scholar google search
Shimura T., Shibata M., Gonda K., Okayama H., Saito M., Momma T., Ohki S., Kono K. (2018) Serum transthyretin level is associated with prognosis of patients with gastric cancer. J. Surg. Res., 227, 145–150. CrossRef Scholar google search
Gericke B., Raila J., Sehouli J., Haebel S., Könsgen D., Mustea A., Schweigert F.J. (2005) Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients. BMC Cancer, 5, 133. CrossRef Scholar google search
Liu L., Wang J., Liu B., Dai S., Wang X., Chen J., Huang L., Xiao X., He D. (2008) Serum levels of variants of transthyretin down-regulation in cholangiocarcinoma. J. Cell. Biochem., 104(3), 745–755. CrossRef Scholar google search
Shimura T., Shibata M., Inoue T., Owada-Ozaki Y., Yamaura T., Muto S., Hasegawa T., Shio Y., Suzuki H. (2019) Prognostic impact of serum transthyretin in patients with non-small cell lung cancer. Mol. Clin. Oncol., 10(6), 597–604. CrossRef Scholar google search
Grenache D.G., Heichman K.A., Werner T.L., Vucetic Z. (2015) Clinical performance of two multi-marker blood tests for predicting malignancy in women with an adnexal mass. Clin. Chim. Acta, 438, 358–363. CrossRef Scholar google search
Hertlein L., Stieber P., Kirschenhofer A., Krocker K., Nagel D., Lenhard M., Burges A. (2012) Human epididymis protein 4 (HE4) in benign and malignant diseases. Clin. Chem. Lab. Med., 50(12), 2181–2188. CrossRef Scholar google search
Malik S., Fu L., Juras D.J., Karmali M., Wong B.Y.L., Gozdzik A., Cole D.E.C. (2013) Common variants of the vitamin D binding protein gene and adverse health outcomes. Crit. Rev. Clin. Lab. Sci., 50(1), 1–22. CrossRef Scholar google search
Speeckaert M., Huang G., Delanghe J.R., Taes Y.E.C. (2006) Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin. Chim. Acta, 372(1-2), 33–42. CrossRef Scholar google search
Bera A., Subramanian M., Karaian J., Eklund M., Radhakrishnan S., Gana N., Rothwell S., Pollard H., Hu H., Shriver C.D., Srivastava M. (2020) Functional role of vitronectin in breast cancer. PLOS One, 15(11), e0242141. CrossRef Scholar google search
Hassan M.I., Waheed A., Yadav S., Singh T.P., Ahmad F. (2008) Zinc alpha 2-glycoprotein: a multidisciplinary protein. Mol. Cancer Res., 6(6), 892–906. CrossRef Scholar google search
Hale L.P., Price D.T., Sanchez L.M., Demark-Wahnefried W., Madden J.F. (2001) Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer. Clin. Cancer Res., 7(4), 846–853. Scholar google search
Bundred N.J., Scott W.N., Davies S.J., Miller W.R., Mansel R.E. (1991) Zinc alpha-2 glycoprotein levels in serum and breast fluids: a potential marker of apocrine activity. Eur. J. Cancer, 27(5), 549–552. CrossRef Scholar google search
Xue Y., Yu F., Yan D., Cui F., Tang H., Wang X., Chen J., Lu H., Zhao S., Peng Z. (2014) Zinc-α-2-glycoprotein: a candidate biomarker for colon cancer diagnosis in Chinese population. Int. J. Mol. Sci., 16(1), 691–703. CrossRef Scholar google search
Filella X., Molina R., Jo J., Bedini J.L., Joseph J., Ballesta A.M. (1992) Tumor associated glycoprotein-72 (TAG-72) levels in patients with non-malignant and malignant disease. Bulletin du Cancer, 79(3), 271–277. Scholar google search
Hu P.-J., Chen M.-Y., Wu M.-S., Lin Y.-C., Shih P.-H., Lai C.-H., Lin H.-J. (2019) Clinical evaluation of CA72-4 for screening gastric cancer in a healthy population: a multicenter retrospective study. Cancers, 11(5), 733. CrossRef Scholar google search
Bray K.R., Koda J.E., Gaur P.K. (1987) Serum levels and biochemical characteristics of cancer-associated antigen CA-549, a circulating breast cancer marker. Cancer Res., 47(22), 5853–5860. Scholar google search
Zamagni C., Martoni A., Cacciari N., Bellanova B., Vecchi F., Pannuti F. (1992) CA-549 serum levels in breast cancer monitoring. Int. J. Biol. Markers, 7(4), 217–221. CrossRef Scholar google search
le Large T.Y.S., Meijer L.L., Paleckyte R., Boyd L.N.C., Kok B., Wurdinger T., Schelfhorst T., Piersma S.R., Pham T.V., van Grieken N.C.T., Zonderhuis B.M., Daams F., van Laarhoven H.W.M., Bijlsma M.F., Jimenez C.R., Giovannetti E., Kazemier G. (2020) Combined expression of plasma thrombospondin-2 and CA19-9 for diagnosis of pancreatic cancer and distal cholangiocarcinoma: a proteome approach. Oncologist, 25(4), e634–e643. CrossRef Scholar google search
(2024) Клинические рекомендации // Министерство здравоохранения Российской Федерации. Retrieved January 17, 2025, from: https://oncologyassociation. ru/clinical-guidelines-update#nav-main. Scholar google search
Arnold M., Soerjomataram I., Ferlay J., Forman D. (2015) Global incidence of oesophageal cancer by histological subtype in 2012. Gut, 64(3), 381–387. CrossRef Scholar google search
d’Journo X.B., Thomas P.A. (2014) Current management of esophageal cancer. J. Thorac. Dis., 6(S2), S253-S264. CrossRef Scholar google search
Lessi F., Franceschi S., Morelli M., Menicagli M., Pasqualetti F., Santonocito O., Gambacciani C., Pieri F., Aquila F., Aretini P., Mazzanti C.M. (2022) Single-cell molecular characterization to partition the human glioblastoma tumor microenvironment genetic background. Cells, 11(7), 1127. CrossRef Scholar google search
Копылов А.М., Антипова О.А., Павлова Г.В. (2022) Молекулярные маркеры нейроонкогенеза при глиобластоме головного мозга. Журнал “Вопросы нейрохирургии” имени Н.Н. Бурденко, 86(6), 99–105. CrossRef Scholar google search
Tan A.C., Ashley D.M., López G.Y., Malinzak M., Friedman H.S., Khasraw M. (2020) Management of glioblastoma: state of the art and future directions. CACancer J. Clin., 70(4), 299–312. CrossRef Scholar google search
Patel A.P., Tirosh I., Trombetta J.J., Shalek A.K., Gillespie S.M., Wakimoto H., Cahill D.P., Nahed B.V., Curry W.T., Martuza R.L., Louis D.N., Rozenblatt-Rosen O., Suvà M.L., Regev A., Bernstein B.E. (2014) Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science, 344(6190), 1396–1401. CrossRef Scholar google search
Опухолевые маркеры: первичный рак печени. Retrived January 23, 2025, from: https://oncology.ru/ specialist/diagnostic/tumor_marker/liver/. Scholar google search
Kashihara T., Ohki A., Kobayashi T., Sato T., Nishizawa H., Ogawa K., Tako H., Kawakami F., Tsuji M., Tamaoka K. (1998) Intrahepatic cholangiocarcinoma with increased serum CYFRA 21-1 level. J. Gastroenterol., 33(3), 447–453. CrossRef Scholar google search
Hiyama E. (2014) Pediatric hepatoblastoma: diagnosis and treatment. Transl. Pediatr., 3(4), 293–299. CrossRef Scholar google search
Meisl C.J., Karakiewicz P.I., Einarsson R., Koch S., Hallmann S., Weiß S., Hemdan T., Malmström P.-U., Styrke J., Sherif A., Hasan M.N., Pichler R., Tulchiner G., Palou J., Rodríguez Faba Ó., Hennenlotter J., Stenzl A., Ritter R., Niegisch G., Grunewald C.M., Schlomm T., Friedersdorff F., Barski D., Otto T., Gössl A., Arndt C., Esuvaranathan K., Kesavan N.R., Zhijiang Z., Kramer M.W., Hennig M.J.P., Ecke T.H. (2022) Nomograms including the UBC® Rapid test to detect primary bladder cancer based on a multicentre dataset. BJU International, 130(6), 754–763. CrossRef Scholar google search
Li M., Men X., Zhang X. (2020) Diagnostic value of carbohydrate antigen 72-4 combined with carbohydrate antigen 15.3 in ovarian cancer, cervical cancer and endometrial cancer. J. BUON, 25(4), 1918–1927. Scholar google search
Fung E.T. (2010) A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin. Chem., 56(2), 327–329. CrossRef Scholar google search
Reilly G.P., Gregory D.A., Scotti D.J., Lederman S., Neiman W.A., Sussman S., Bean L.M., Ekono M.M. (2023) A real-world comparison of the clinical and economic utility of OVA1 and CA125 in assessing ovarian tumor malignancy risk. J. Comp. Eff. Res., 12(6), e230025. CrossRef Scholar google search
Toledo S.P.A., Lourenço D.M.J., Santos M.A., Tavares M.R., Toledo R.A., Correia-Deur J.E. (2009) Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma. Clinics (Sao Paulo), 64(7), 699–706. CrossRef Scholar google search
Kim H., Kim Y.N., Kim H.I., Park S.Y., Choe J.-H., Kim J.-H., Kim J.S., Chung J.H., Kim T.H., Kim S.W. (2017) Preoperative serum thyroglobulin predicts initial distant metastasis in patients with differentiated thyroid cancer. Sci. Rep., 7, 16955. CrossRef Scholar google search
Сергеева Н.С., Маршутина Н.В., Солохина М.П., Алентов И.И., Парилова Н.К., Зенкина Е.В., Скачкова Т.Е. (2014) Современные представления о серологических опухолеассоциированных маркерах и их месте в онкологии. Успехи молекулярной онкологии, 1(1), 69–80. Scholar google search
Kyle R.A., Gertz M.A., Witzig T.E., Lust J.A., Lacy M.Q., Dispenzieri A., Fonseca R., Rajkumar S.V., Offord J.R., Larson D.R., Plevak M.E., Therneau T.M., Greipp P.R. (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin. Proc., 78(1), 21–33. CrossRef Scholar google search
Basheeth N., Patil N. (2019) Biomarkers in head and neck cancer an update. Indian J. Otolaryngol. Head Neck Surg., 71(Suppl 1), 1002–1011. CrossRef Scholar google search
Vigneswaran N., Williams M.D. (2014) Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral Maxillofac. Surg. Clin. North Am., 26(2), 123–141. CrossRef Scholar google search
Singh P., Barpande S.R., Bhavthankar J.D., Mandale M.S., Bhagwat A.U. (2017) Serum Cyfra 21-1 levels in oral squamous cell carcinoma patients and its clinicopathologic correlation. Indian J. Dent. Res., 28(2), 162–168. CrossRef Scholar google search
Кочурова Е.В., Кудасова Е.О., Николенко В.Н., Панферова О.И. (2022) Роль биомаркеров ротовой жидкости в диагностике рака слизистой оболочки полости рта. Вопросы Онкологии, 68(5), 565–570. CrossRef Scholar google search
Topuz M.F., Binnetoglu A., Yumusakhuylu A.C., Sarı M., Baglam T., Gerin F. (2017) Circulating calprotectin as a biomarker of laryngeal carcinoma. Eur. Arch. Otorhinolaryngol., 274(6), 2499–2504. CrossRef Scholar google search
Schapher M., Wendler O., Gröschl M., Schäfer R., Iro H., Zenk J. (2009) Salivary leptin as a candidate diagnostic marker in salivary gland tumors. Clin. Chem., 55(5), 914–922. CrossRef Scholar google search
Zhang H., Ren D., Jin X., Wu H. (2020) The prognostic value of modified Glasgow Prognostic Score in pancreatic cancer: a meta-analysis. Cancer Cell Int., 20, 462. CrossRef Scholar google search
Yang M., Lin S.-Q., Liu X.-Y., Tang M., Hu C.-L., Wang Z.-W., Zhang Q., Zhang X., Song M.-M., Ruan G.-T., Zhang X.-W., Liu T., Xie H.-L., Zhang H.-Y., Liu C.-A., Zhang K.-P., Li Q.-Q., Li X.-R., Ge Y.-Z., Liu Y.-Y., Chen Y., Zheng X., Shi H.-P. (2023) Association between C-reactive proteinalbumin- lymphocyte (CALLY) index and overall survival in patients with colorectal cancer: From the investigation on nutrition status and clinical outcome of common cancers study. Front. Immunol., 14, 1131496. CrossRef Scholar google search
Chen Y.-R., Chen Y.-L., Ouyang S.-S., Xu H.-W., Li P., He L.-J., Zhu S.-L. (2020) Prognostic efficacy of preoperative mGPS, SIS and LCS in patients with gastric cancer. Clin. Chim. Acta, 511, 81–89. CrossRef Scholar google search
Kumari S. (2018) Serum biomarker based algorithms in diagnosis of ovarian cancer: a review. Indian J. Clin. Biochem., 33(4), 382–386. CrossRef Scholar google search
